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Abstract
Ameloblastoma (AM) is a benign yet locally aggressive tumor with high recurrences. Currently, the
underlying pathophysiology remains elusive and radical surgery remains the most definitive treatment
with severe morbidities. Our group first reported that AM harbors a subpopulation of tumor epithelial
stem-like cells (AM-EpiSCs). Herein, this study further explored whether LGR5+ epithelial cells in AM
possess unique stem-like cell properties and their potential contribution to the pathogenesis and
recurrence of AM. Our findings demonstrated that LGR5 and stem cell-related genes were simultaneously
expressed in a subpopulation of AM epithelial cells, both in vivo and in vitro, which were markedly
enriched under the 3D-spheroid culture condition. As compared to LGR5- counterparts, LGR5+ AM
epithelial cells showed increased expression of several critical genes involved in the regulation of
epithelial-mesenchymal transition (EMT) and stem cell pluripotency, and functionally, exhibited enhanced
capacity to form 3D-spheroids and generate human tumor 3D-organoids, which recapitulated
characteristic histopathologic features of distinct subtypes of solid AM. Interestingly, AM derived
mesenchymal stromal cells (AM-MSCs) and their secretomes or extracellular vesicles (EVs) significantly
promoted the generation of LGR5+ AM-EpiSCs both in vitro and in vivo. Furthermore, treatment with a
selective BRAFV600E inhibitor, Vemurafenib, unexpectedly enriched the proportion of LGR5+ AM-EpiSCs in
AM 3D-organoids, which may explain the therapeutic resistant and recurrent properties of AM conferred
by this unique subpopulation of AM-EpiSCs. Therefore, the tumor 3D-organoids generated by LGR5+ AMEpiSCs provided a novel ex vivo platform for mechanistic studies of human AM and high throughput
screening of targeted therapeutic drugs. These findings suggest that LGR5+ AM-EpiSCs play a pivotal role
in pathogenesis and progression of AM and targeted inhibition of both BRAF and LGR5 potentially serves
a novel non-surgical adjuvant therapeutic approach for this benign yet aggressively destructive jaw tumor.
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ABSTRACT
THE ROLE OF LGR5+ EPITHELIAL STEM-LIKE CELLS IN 3DORGANOID MODELING AND PATHOGENESIS OF
AMELOBLASTOMA
Ting-Han Chang
Anh D. Le and Qunzhou Zhang

Ameloblastoma (AM) is a benign yet locally aggressive tumor with high
recurrences. Currently, the underlying pathophysiology remains elusive and
radical surgery remains the most definitive treatment with severe morbidities. Our
group first reported that AM harbors a subpopulation of tumor epithelial stem-like
cells (AM-EpiSCs). Herein, this study further explored whether LGR5+ epithelial
cells in AM possess unique stem-like cell properties and their potential
contribution to the pathogenesis and recurrence of AM. Our findings
demonstrated that LGR5 and stem cell-related genes were simultaneously
expressed in a subpopulation of AM epithelial cells, both in vivo and in vitro,
which were markedly enriched under the 3D-spheroid culture condition. As
compared to LGR5- counterparts, LGR5+ AM epithelial cells showed increased
expression of several critical genes involved in the regulation of epithelialmesenchymal transition (EMT) and stem cell pluripotency, and functionally,
exhibited enhanced capacity to form 3D-spheroids and generate human tumor
3D-organoids, which recapitulated characteristic histopathologic features of
v

distinct subtypes of solid AM. Interestingly, AM derived mesenchymal stromal
cells (AM-MSCs) and their secretomes or extracellular vesicles (EVs)
significantly promoted the generation of LGR5+ AM-EpiSCs both in vitro and in
vivo. Furthermore, treatment with a selective BRAFV600E inhibitor, Vemurafenib,
unexpectedly enriched the proportion of LGR5+ AM-EpiSCs in AM 3D-organoids,
which may explain the therapeutic resistant and recurrent properties of AM
conferred by this unique subpopulation of AM-EpiSCs. Therefore, the tumor 3Dorganoids generated by LGR5+ AM-EpiSCs provided a novel ex vivo platform for
mechanistic studies of human AM and high throughput screening of targeted
therapeutic drugs. These findings suggest that LGR5+ AM-EpiSCs play a pivotal
role in pathogenesis and progression of AM and targeted inhibition of both BRAF
and LGR5 potentially serves a novel non-surgical adjuvant therapeutic approach
for this benign yet aggressively destructive jaw tumor.
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The part of this dissertation was reorganized from the article accepted by the

journal of Cell Death & Disease.
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These materials are not contained in the Footnote 1.

1

LGR5+ epithelial tumor stem-like cells generate a 3D-organoid model for ameloblastoma. TingHan Chang, Rabie M. Shanti, Yanfang Liang, Jincheng Zeng, Shihong Shi, Faizan Alawi, Lee
Carrasco, Qunzhou Zhang, and Anh D. Le. Accepted for publication in Cell Death & Disease.
2

Chapter 1.4-1.6, 2.13, 2.15, 3.8-3.10, 4.3-4.4. Table 1, 2 and Figure 1.1-1.3,1.5, 2.1-2.2, 3.1823.
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CHAPTER 1: INTRODUCTION
1.1 Classification and epidemiology of ameloblastoma
Ameloblastoma (AM), one of the most common odontogenic epithelial
tumors, has an estimated global incidence of 0.5 cases per million, and most
cases are diagnosed at 30-60 years of age. AM accounts for 1% of all oral
tumors and 11.7 to 60.3% of all odontogenic tumors1. AM is a benign yet locally
aggressive tumor with a high recurrent rate in comparison with other benign
odontogenic cysts or tumors. The overall recurrent rate of AM is 31%, ranging
from 65% for conservative surgery to 11% for radical surgery2, even though its
malignant transformation and/or metastasis are less reported. The WHO has
recently

updated

the

classification

of

AM

into

three

categories,

AM

(solid/multicystic type), unicystic type, and peripheral/extraosseous type, among
which the solid/multicystic type accounts for about 71.3% of all AM cases and
manifests a high recurrence rate (Figure 1.1)3,4. For large and aggressive lesions,
a radical surgical approach is usually recommended with at least 1 cm margin to
prevent recurrence5; however, incurs severe morbidities associated with large
jaw defects, impaired oral functions and facial esthetics that require
comprehensive tissue reconstruction and oral rehabilitation, compromise patient
quality of life and raise the overall health care cost 1,6. To date, the
pathophysiology of AM remains poorly understood. Previous studies have found
several genetic mutations in AM, including mitogen-activated protein kinase
1

(MAPK)

and

non-MAPK

pathway,

such

as

sonic hedgehog

pathway,

phosphatidylinositol 3-kinase (PI3K) pathway and Wnt signaling pathway (Figure
1.2)7,8. Among these mutations, BRAFV600E is the most common one, accounting
for 46-82%7-12, but has no significant correlation with tumor recurrence (Figure
1.3 and Table 1). BRAF is the gene that encodes B-Raf protein, which is a
member of the Raf kinase family involved in regulating the MAPK pathway.
BRAFV600E is a point mutation at codon 600 where valine is replaced by glutamic
acid. A specific BRAFV600E inhibitor, Vemurafenib, inhibits the activity of
BRAFV600E kinase by binding to its ATP-binding site. Clinically, Vemurafenib has
been utilized to treat melanoma, but a high drug resistance rate has been
reported in melanoma patients13. Currently, an active clinical trial (NCT02367859)
on AM therapy has been ongoing with the combinatory use of Dabrafenib (a
BRAF inhibitor) and Trametinib (a MEK inhibitor), and only a partial response to
the treatment with either a single BRAF inhibitor or combined a MEK inhibitor has
been reported in AM patients (Table 2)14-17. Therefore, further studies are
necessary to delineate the mechanisms underlying AM pathogenesis that may
hold promises in the development of novel drugs as a non-surgical adjunctive
treatment of this benign but aggressive odontogenic tumor.
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Figure 1.1 Classification of ameloblastoma (AM). A The Diagram was organized
according to 2017 WHO classification of head and neck tumors3. The classification of
AM has been updated into three categories, including AM (solid/multicystic), unicystic
and peripheral/extraosseous. B The pie chart was modified from the global incidence of
AM by Hendra, F. N. et al.4, herein the most common type is solid AM with around
71.3%. C Histopathology of different subtypes of solid AM. Left, the follicular type is the
most common type, which consists of islands of odontogenic epithelium surrounding with
columnar to cuboidal peripheral cells (ameloblast-like). The epithelium arranges in a
palisading pattern with hyperchromatic nuclei and reverses polarity. The inner cells
resemble stellate reticulum with loosely arranged angular cells that may undergo cystic
changes. The stroma is moderate to highly collagenized. Middle, the second common
type is the plexiform type which consists of anastomosing strands with an inconspicuous
stellate reticulum, and the peripheral epithelial cells are less pronounced than the
follicular type. The connective tissue is loose and often undergoes cystic changes. Right,
The desmoplastic type consists of cuboidal to flat peripheral cells with central spindle
cells and densely collagenous stroma. Scale bar: 50μm.

3

Figure 1.2 Mutations in signaling pathways of AM. The mutations in AM were marked
with red color and these involved pathways are essential for cell proliferation and
survival. A Somatic mutation of CTNNB1, a gene that encodes a protein called β-catenin
in the canonical Wnt signaling pathway. B Mutation of FGFR2, a class V receptor
tyrosine kinase (RTK), activates both MAPK (right) and PI3K signaling pathways (left).
Right: both RAS and RAF in the downstream of MAPK pathway have mutations. Left:
the mutation of PIK3CA, the gene that encodes p110 protein, a catalytic subunit of PI3K.
C The smoothened (SMO) mutation in the hedgehog signaling pathway. The diagram
was generated by using SMART SERVIER MEDICAL ART.

4

Figure 1.3 BRAFV600E mutation in AM. Data are pooled from four original articles, and
the raw data are presented in Table 1. A Around 62% BRAFV600E mutation in 85 patients.
B BRAFV600E mutation is significantly higher in the mandible (93%) than the maxilla.
p<0.0001, Fisher’s exact test. C BRAFV600E was found in both unicystic and solid AM,
including different histologic subtypes of solid AM, but had a lower preference in
plexiform AM compared with the wild type BRAF group. Besides, this dataset showed no
desmoplastic AM in the wild type BRAF group. p=0.0071 Chi-square test. D BRAFV600E
had no significant different preference in sex distribution compared with the wild type
BRAF group. NS= not significant. Fisher’s exact test. E BRAFV600E mutation occurred in
younger diagnosis age. Data are mean ± SD, two-tailed unpaired Student’s t-tests,
*p<0.05. F No significant difference in the recurrent rate between BRAFV600E mutation
and wild type groups. NS=not significant. Fisher’s exact test.
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Table 1. BRAFV600E mutation in AM.
ID (Author_case number)

Histological type BRAFV600E Recurrence

Sex

Age

Location

Diniz et al._0110

F

23

Mandible

Unicystic

WT

NA

al._0710

M

48

Mandible

Follicular

WT

NA

Diniz et al._0810

M

8

Maxilla

Follicular

WT

Primary

Kurppa et al._039

M

61

Mandible

Plexiform

WT

Primary

al._079

M

36

Mandible

Follicular

WT

Primary

Kurppa et al._099

M

32

Mandible

Plexiform

WT

Recurrence

al._139

M

84

Mandible

Follicular

WT

Primary

Kurppa et al._169

F

61

Mandible

Mix

WT

Primary

Kurppa et al._179

M

69

Mandible

Plexiform

WT

Primary

al._189

M

77

Mandible

Plexiform

WT

Recurrence

Kurppa et al._199

M

69

Mandible

Plexiform

WT

Primary

Kurppa et al._249

M

31

Mandible

Follicular

WT

Primary

al._1012

F

52

NA

Plexiform

WT

NA

Soltani et al._1512

F

16

NA

Plexiform

WT

NA

al._2212

M

35

NA

Follicular

WT

NA

Soltani et al._2512

M

31

NA

Follicular

WT

NA

Soltani et al._2812

Diniz et

Kurppa et

Kurppa et

Kurppa et

Soltani et

Soltani et

M

33

NA

Follicular

WT

NA

al._018

F

57

Maxilla

Plexiform

WT

Primary

Sweeney et al._028

M

73

Maxilla

Mix

WT

Recurrence

Sweeney et al._038

M

70

Mandible

Follicular

WT

Primary

al._048

M

66

Maxilla

Plexiform

WT

Recurrence

Sweeney et al._058

F

51

Maxilla

Plexiform

WT

Recurrence

al._068

F

29

Maxilla

Plexiform

WT

Primary

Sweeney et al._078

NA

NA

Maxilla

Plexiform

WT

NA

Sweeney et al._088

M

77

Maxilla

Plexiform

WT

Recurrence

al._098

M

62

Maxilla

Plexiform

WT

Primary

Sweeney et al._238

M

79

Mandible

NA

WT

Primary

Sweeney et al._248

M

61

Maxilla

Follicular

WT

Primary

al._258

M

65

Maxilla

Follicular

WT

Primary

Sweeney et al._268

Sweeney et

Sweeney et

Sweeney et

Sweeney et

Sweeney et

NA

NA

Mandible

Follicular

WT

NA

al._278

F

91

Mandible

Follicular

WT

Primary

Sweeney et al._288

F

47

Mandible

Plexiform

WT

Recurrence

Diniz et al._0210

M

NA

Mandible

Unicystic

Mutant

NA

Sweeney et

6

ID (Author_case number)

Histological type BRAFV600E Recurrence

Sex

Age

Location

Diniz et al._0310

F

10

Mandible

Unicystic

Mutant

NA

Diniz et al._0410

F

21

Mandible

Unicystic

Mutant

Primary

Diniz et al._0510

M

14

Mandible

Unicystic

Mutant

Primary

al._0610

M

38

Maxilla

Unicystic

Mutant

Primary

Diniz et al._0910

M

NA

Mandible

Granular

Mutant

NA

al._1010

F

41

Mandible

Follicular

Mutant

NA

Diniz et al._1110

M

46

Mandible

Follicular

Mutant

Primary

Diniz et al._1210

F

28

Mandible

Follicular

Mutant

NA

al._1310

F

39

Mandible

Follicular

Mutant

Primary

Diniz et al._1410

F

9

Mandible

Plexiform

Mutant

NA

Diniz et al._1510

M

75

Maxilla

Follicular

Mutant

Primary

al._1610

F

28

Maxilla

Desmoplastic

Mutant

Primary

Diniz et al._1710

Diniz et

Diniz et

Diniz et

Diniz et

M

25

Mandible

Desmoplastic

Mutant

Primary

al._019

M

66

Mandible

Follicular

Mutant

Primary

Kurppa et al._029

F

70

Mandible

Follicular

Mutant

Primary

Kurppa et al._049

F

27

Mandible

Follicular

Mutant

Primary

al._059

F

24

Mandible

Plexiform

Mutant

Primary

Kurppa et al._069

F

50

Mandible

Plexiform

Mutant

Primary

Kurppa et al._089

M

47

Mandible

Follicular

Mutant

Primary

al._109

M

46

Mandible

Follicular

Mutant

Recurrence

Kurppa et al._119

M

14

Mandible

Plexiform

Mutant

Primary

al._129

F

34

Mandible

Follicular

Mutant

Recurrence

Kurppa et al._149

F

18

Mandible

Follicular

Mutant

Primary

Kurppa et al._159

M

16

Mandible

Plexiform

Mutant

Primary

al._209

M

43

Mandible

Follicular

Mutant

Primary

Kurppa et al._219

F

44

Mandible

Plexiform

Mutant

Primary

Kurppa et al._229

M

33

Mandible

Follicular

Mutant

Recurrence

al._239

F

46

Mandible

Plexiform

Mutant

Recurrence

Soltani et al._0312

M

87

NA

Follicular

Mutant

NA

al._0512

M

58

NA

Follicular

Mutant

NA

Soltani et al._0612

M

46

NA

Plexiform

Mutant

NA

Soltani et al._0912

M

51

NA

Plexiform

Mutant

NA

al._1212

M

30

NA

Plexiform

Mutant

NA

Soltani et al._1612

M

30

NA

Plexiform

Mutant

NA

Kurppa et

Kurppa et

Kurppa et

Kurppa et

Kurppa et

Kurppa et

Soltani et

Soltani et
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ID (Author_case number)

Histological type BRAFV600E Recurrence

Sex

Age

Location

Soltani et al._2012

M

78

NA

Follicular

Mutant

NA

Soltani et al._2312

F

50

NA

Plexiform

Mutant

NA

Soltani et al._2412

M

22

NA

Follicular

Mutant

NA

al._2612

F

37

NA

Follicular

Mutant

NA

Soltani et al._2912

M

41

NA

Follicular

Mutant

NA

al._3312

F

26

NA

Plexiform

Mutant

NA

Sweeney et al._118

NA

NA

Mandible

Mix

Mutant

NA

Sweeney et al._128

M

59

Mandible

Follicular

Mutant

Recurrence

al._138

NA

NA

Mandible

Follicular

Mutant

NA

Sweeney et al._148

M

45

Mandible

Follicular

Mutant

Primary

Sweeney et al._158

M

70

Mandible

Mix

Mutant

Recurrence

al._168

NA

NA

Mix

Mutant

NA

Sweeney et al._178

NA

NA

Mix

Mutant

NA

Sweeney et al._188

M

83

Mandible
Frontal
bone
Mandible

Plexiform

Mutant

Primary

Sweeney et al._198

NA

NA

Mandible

NA

Mutant

NA

al._208

NA

NA

Mandible

NA

Mutant

NA

Sweeney et al._218

NA

NA

Mandible

NA

Mutant

NA

al._228

NA

NA

Mandible

NA

Mutant

NA

Soltani et

Soltani et

Sweeney et

Sweeney et

Sweeney et

Sweeney et

This table pools BRAFV600E and BRAFWT ameloblastoma cases from previous studies in
the comparation of sex, age, location, histological type and recurrence. M, male; F,
female; WT, wild type; NA, not available.
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Table 2. Clinical reports of targeting BRAFV600E in AM.
Author

Sex

Age

Diagnosis

Mutation

Treatment

Follow up/
tool

Outcome

Kaye et
al.14

M

40

Recurrent
ameloblastom
a of left
mandible,
bilateral neck
and bilateral
lung
metastasis

BRAF
V600E

Dabrafenib
150 mg
BID;
trametinib 2
mg QD

20 weeks/
CT scan

Partial
response

Tan et
al.16

M

85

Recurrent AM,
left mandible
with pathologic

BRAF
V600E

Dabrafenib
150 mg BID
for 73 days,
1.5 months
later under
surgery
treatment

75 days/
CT scan

Cystic change
with same
tumor size

16 weeks/
surgical
specimen

> 90% tumor

fracture

volume
reduction in
the specimen

Faden
et al.15

F

83

Recurrent AM,
right mandible

BRAF
V600E

Dabrafenib
75 mg BID
(50%
reduction of
dose due to
clinical
comorbiditi
es)

12 months/
MRI

75% reduction
in tumor
volume

Fernan
des et
al.17

F

29

Recurrent AM,
left mandible
status post
operation

BRAF
V600E

Vemurafeni
b 960 mg
BID

11 months/
MRI

Partial
response

BRAF
V600E

Dabrafenib
150 mg
BID;
trametinib 2
mg QD

12 weeks/
PET/CT
scan;30
weeks/ NA

Complete
response

Undiagnosed
lesion of right
cavernous
sinus
Brunet
et al.18

F

26

Metastasis AM
of bilateral
lung

This table is a summary of clinical case reports for advanced ameloblastoma cases
treated with a BRAFV600E inhibitor (dabrafenib or vemurafenib) alone or combined with a
MEK inhibitor (trametinib) orally. AM, ameloblastoma; M, male; F, female; QD, once
daily, BID, twice daily; CT, computerized tomography; MRI, Magnetic resonance imaging;
PET, positron emission tomography; NA, not available.
9

1.2 Plasticity of cancer stem cells— bidirectional EMT process,
the hybrid EMT intermediate cells
Cancer stem cells (CSCs), or tumor-initiating cells (TICs), have the
capabilities of self-renewal and differentiation into non-CSCs to repopulate the
cancer mass. CSCs have been demonstrated to contribute to tumorigenesis,
progression, metastasis, therapeutic resistance, and recurrence 19,20. Epithelialmesenchymal transition (EMT) is a dynamic process, during which epithelial cells
undergo loss of cell junctions and spindle shape-like cell morphological changes
and gain increased cell motility, all properties characteristic of mesenchymal
cells21,22. EMT process plays a critical role in embryonic development, tissue
remodeling/homeostasis, and wound healing, and a variety of pathological
settings22,23. In tumor microenvironment, a portion of tumor epithelial cells
undergo dynamic bidirectional EMT and mesenchymal-epithelial transition (MET)
process, the determinant of cell plasticity that contributes to tumor initiation, CSC
formation, and is closely associated with the development of several cancer
hallmarks22. EMT intermediate cells, or hybrid cells, are endowed with both
epithelial and mesenchymal cell features and contribute to tumor initiation,
progression, metastasis, and drug resistance21-23. However, much less work has
been done to explore the potential role of EMT and TICs in the development of
benign epithelial tumors. Recently, our group has shown that AM tissues harbor
a proportion of epithelial cells (AM epithelial cells) which simultaneously express
EMT regulatory transcription factors (TFs) such as ZEB1, Slug, and Snail as well
as stem cell-related markers such as ALDH1, BMI-1, and SOX2. These proteins
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were up-regulated in AM epithelial cells when co-cultured with AM-derived
mesenchymal stromal cells (AM-MSCs)24, thus supporting the notion that the
subpopulation of AM epithelial cells are endowed with both EMT and stem-like
cell properties (AM-EpiSCs). However, to date, there is still a lack of consistent
cell surface markers to identify these EMT intermediate cells with stem-like cell
properties (AM-EpiSCs) and their potential role in the pathogenesis and
progression of AM remains largely unknown.

1.3 LGR5+ stem cells in normal organs and tumors
Leucine-rich repeat-containing G-protein coupled receptor (LGR) proteins are a
unique class of evolutionarily conserved seven-transmembrane (7TM) receptors
characterized by a large extracellular region (ectodomain) that harbors multiple
imperfect copies of leucine-rich repeat protein interaction domain (Figure 1.4 A)25.
LGR5, a family member of LGR proteins, can activate Wnt/β-catenin pathway
through binding with its ligands, R-spondin family (R-spondin 1 to 4) (Figure 1.4
B)25,26, and has been identified as an epithelial stem cell marker in multiple
developmental organs, such as the root cervical loop, taste bud, intestine, and
hair follicle25,27,28. Meanwhile, LGR5 has also been reported as a putative marker
for cancer stem cells (CSCs) in several types of malignant cancers, e.g. basal
cell carcinoma, glioma, and gastrointestinal (GI) cancers29-34. Functionally, LGR5
has been shown to promote EMT process and metastasis in hepatocellular
carcinoma, colon cancer, and glioma33-35 and to predict poor survival of glioma
patients34. The development of odontogenic tumors, including ameloblastoma,
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has been linked to the enamel organ, e.g. remnants of odontogenic epithelium,
the migrating epithelium at the cervical loop, and lining of odontogenic cyst 36,37.
Several studies have also reported LGR5 expression in odontogenic epithelial
stem cells38-41, suggesting that LGR5 may represent a putative epithelial stem
cell surface marker in both normal and tumorous odontogenic tissues.
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Figure 1.4 LGR5-mediated signaling pathways. A Leucine-rich repeat-containing Gprotein coupled receptor (LGR) proteins are a unique class of evolutionarily conserved
seven-transmembrane (7TM) receptors characterized by a large extracellular region
(ectodomain) that harbors multiple imperfect copies of leucine-rich repeat (LRR) protein
interaction domain. B R-spondins bind to LGR5 ectodomain at the horseshoe-shaped
LRR surface, but not C-terminal cap, leading to the activation of the Wnt/β-catenin
signaling pathway. In addition, the extended loop of the C-terminal LRR cap can bind to
the antibody and activate LGR5 signaling in a ligand-independent manner42.
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1.4 Tumor microenvironment in the regulation of tumor
progression
In epithelial tumor microenvironment, abundant stromal cells, particularly,
the cancer associated fibroblasts (CAFs), surround epithelial tumor islands and
play an important role in tumorigenesis and progression of various types of
malignancies43. Recently, our group showed that AM-MSCs are essential for the
survival of AM epithelial cells in vivo and AM-MSCs derived interleukin (IL)-6 can
promote the expression of stem cell- and EMT-related genes in AM epithelial
cells24.
Paracrine secretomes contain a large panel of biological soluble factors.
Exosomes, a subtype of extracellular vesicles (EVs) released by all kinds of cells,
have a size ranged from 30~200nm and contain a variety of biological
components such as proteins, lipids, and nucleic acid that play an important role
in intercellular communication44. Recently, an increasing body of evidence has
revealed the important role of cancer-derived exosomes in tumorigenesis and
these circulating exosomes can be employed as biomarkers for early diagnosis
and prognosis45-47. However, the role of AM-MSCs-derived secretomes in the
regulation of LGR5+ EpiSCs in AM is unknown.

1.5 Organoid model in the study of tumor biology
Two-dimensional (2D) monolayer cell culture is a popular and stable method
to study tumor cell behavior in vitro. However, the 2D culture involves a single
type of cells and fails to reflect in situ tumor structure and the heterogeneity of its
tumor microenvironment48,49. To overcome the drawbacks of the conventional 2D
14

culture, researchers endeavored to develop 3D-spheroid culture, whereby cells in
a suspension culture system aggregate into 3D-spheroid structures that can
partially mimic certain properties, e.g. hypoxia and cell-cell interactions of in vivo
tumor microenvironment50. In recent years, much progress has been made in the
development of 3D-organoid culture, which is based on cell-cell and cellextracellular matrix (ECM) interactions to generate organ-like structures49. The
3D-organoid model can recapitulate the major properties of the target tissues or
organs, thus having provided a useful alternative ex vivo platform to replace
animal models for mechanistic studies in stem cell biology, tissue homeostasis,
and disease modeling48,50. Even though 3D-organoids have been extensively
employed in the study of a variety of malignant tumors, much less is done in the
field of benign tumor. Due to the lack of an established animal model for human
ameloblastoma, herein, it is crucial to establish an AM-organoid model as an
alternative for further mechanistic studies and therapeutic drug screening.

1.6 Hypothesis
LGR5 has been identified as an epithelial stem cell marker in multiple
developmental organs and cancer stem cells (CSCs)
demonstrated

to

contribute

to

tumorigenesis,

25,27-30.

CSCs have been

progression,

metastasis,

therapeutic resistance, and recurrence19,20. EMT intermediate cells, or hybrid
cells, are endowed with both epithelial and mesenchymal cell features and
contribute to CSC capabilities, such as tumor initiation, progression, metastasis,
and drug resistance19-23. Our group previously showed that AM-MSCs are
15

essential for the survival of AM epithelial cells in vivo and AM-MSCs derived
interleukin (IL)-6 can promote the expression of stem cell- and EMT-related
genes in AM epithelial cells24. Based on these findings, I hypothesize that
LGR5+ AM epithelial cells represent a subpopulation of EMT hybrid cells
with unique stem-like cell properties driven by stromal cell-derived
secretomes, which contribute to the pathogenesis and recurrence of AM
(Figure 1.5). Studies in this thesis have demonstrated the potential role of LGR5+
intermediate stem-like AM epithelial cells in the pathogenesis and organoid
formation in ameloblastoma, and the tumor 3D-organoids formed by LGR5+ AMEpiSCs provided a novel ex vivo platform for further mechanistic studies and
screening of targeted therapeutic drugs for the treatment of this benign yet
aggressively destructive jaw tumor.
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Figure 1.5 Hypothesis and aims. The central hypothesis is that LGR5+ AM epithelial
cells represent a subpopulation of tumor stem-like cells and confer EMT phenotypes. To
confirm this hypothesis, this study proposed the following three specific aims. Aim 1: To
explore whether LGR5+ epithelial cells represent a subpopulation of epithelial stem-like
cells in AM and their potential roles in the pathogenesis and recurrence of AM. Aim 2:
To establish 3D organoids by using LGR5+ AM epithelial cells, allowing for further
mechanistic and therapeutic intervention studies. Aim 3: To uncover the role of AMMSCs in the regulation of EMT process and stem cell properties in LGR5+ AM epithelial
cells.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Experimental design
Aim 1: To explore whether LGR5+ epithelial cells represent a subpopulation
of epithelial stem-like cells in AM and their potential roles in the pathogenesis
and recurrence of AM (Figure 2.1). This study collected fifteen human AM
samples (three fresh tissues and twelve formalin-ﬁxed parafﬁn-embedded tissues)
to evaluate histological features and culture epithelial cells (AM-EpiCs) and
mesenchymal cells (AM-MSCs). To determine the stem cell and EMT properties
of LGR5+ AM epithelial cells in vitro, Lg5+ epithelial cells were sorted out and
compared their properties and functions with parental, LGR5 - counterparts,
including: (i) The expression of stem cell-related genes and EMT TFs; (ii) Selfrenewal capability via sphere-forming assay; (iii) Migration capacities. To
determine whether LGR5 is a functional marker, the proliferation and stem cell
and EMT properties of AM-EpiCs after stimulated with its ligands (R-spondin 1
and 2) were evaluated.
Aim 2: To establish 3D organoids using LGR5+ AM epithelial cells (Figure
2.2). This study utilized both primary AM cells (follicular type) and one AM cell
line (plexiform type) to create AM-organoids and optimized the culture conditions,
e.g. culture media, cell density, and small molecules, for 3D organoid culture with
LGR5+ AM epithelial cells alone or in combination with AM-MSCs. Then, I
subcutaneously transplanted ex vivo cultured 3D AM-organoids into nude mice to
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evaluate the stem cell properties of LGR5+ AM epithelial cells in vivo by
comparison of the self-renewal, proliferation and propagation capabilities of
parental, LGR5-, and LGR5+ AM epithelial cells. Finally, this study determined
whether a specific BRAF inhibitor can extirpate ex vivo organoid formation.
Aim 3: To uncover the role of AM-MSCs in the regulation of EMT process
and stem cell properties in LGR5+ AM epithelial cells. The stromal effects on
EMT and stem cell properties in LGR5+ AM epithelial cells were determined.
Parental, sorted LGR5-, and LGR5+ AM epithelial cells were co-cultured with AM
mesenchymal stromal cells (AM-MSCs) or stimulated with AM-MSC derived
secretomes, and then the expression of LGR5, EMT TFs, and stem cell-related
genes was determined. Finally, the 3D AM-organoids derived from AM-EpiCs
and AM-MSCs ex vivo (Figure 2.2) were established to create a platform for
future mechanistic studies.
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Figure 2.1 To identify whether LGR5+ AM epithelial cells represent a subpopulation
of stem-like cells in AM. This study collected fifteen human AM tissues and analyzed
the expression of LGR5 in both tissue samples and isolated primary epithelial cells form
fresh tissues. Then, the stem cell- and EMT-properties in sorted LGR5- and LGR5+ AM
epithelial cells were compared both in vitro and in vivo.
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Figure 2.2 To generate AM-organoid models. The AM-organoid models were
generated from either AM epithelial cells alone or combined AM epithelial cells and
MSCs. Then, the ex vivo organoids were utilized to test the therapeutic effect of a
specific BRAFV600E inhibitor and to evaluate the potential role of LGR5+ AM-EpiSCs in
AM pathogenesis following subcutaneous transplantation into nude mice.
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2.2 Tissue collection
The study was conducted in accordance with human subject research
guidelines and a protocol approved by the institutional review board (IRB) at
University of Pennsylvania (UPenn) (IRB#817407) and focused on solid AM, the
most common histopathological variant of this benign tumor with a high recurrent
rate. Three fresh primary solid AM samples, including one follicular type, one
follicular/plexiform mixed type, and one desmoplastic type, were obtained
immediately post-surgical procedures from the Department of Oral and
Maxillofacial Surgery of Penn Medicine Hospital of UPenn. Meanwhile, six
dentigerous cysts were also collected as the control. In addition, a total of 12
formalin-ﬁxed parafﬁn-embedded blocks of solid AM samples were retrieved from
the archives at Departments of Pathology of University of Pennsylvania School of
Dental Medicine (IRB#817407), Dongguan Hospital Affiliated to Medical College
of Jinan University, and the Fifth People's Hospital of Dongguan, which were also
approved by the research and ethical committee of the two hospitals in China
(Guangdong, China). Informed consent was obtained from all subjects.
Diagnoses were made by two independent pathologists, including a boardcertiﬁed oral and maxillofacial pathologist, based on the WHO classiﬁcation
(2017) of odontogenic tumors.

2.3 Cell culture
An immortalized AM cell line (AM-1) was generously provided by Dr.
Hidemitsu Harada at Iwate Medical University and cultured with defined serum22

free keratinocyte growth medium (KGM-2 BulletKit, Lonza). Primary AM epithelial
cells and AM-MSCs were isolated as previously described24. Briefly, at least 3-6
mm3 of fresh human AM tissues were minced into 0.5-1 mm3 pieces followed by
enzymatic digestion with 0.2% collagenase I (Gibco) for 1 hour in a 37C shaking
incubator. For AM epithelial cells, the dissociated cells were seeded in gelatincoated tissue culture dishes (2x104/cm3) in defined KGM-2 culture medium
(Lonza) at 37C in a humidified incubator with 5% CO2. For AM-MSCs, the
dissociated cells were seeded in tissue culture dishes (2x104/cm3) in complete αMEM medium (α-MEM with 10% FBS and 1% penicillin/streptomycin) at 37C in
a humidified incubator with 5% CO2 After 48 hours, the non-adherent cells were
removed, and fresh media were replenished every three days. When cells were
at 75%-95% confluence, AM epithelial cells were sub-cultured following cell
dissociation with 1× Accutase solution (Sigma) and AM-MSCs were passaged
using 0.05% Trypsin-EDTA solution (Fisher Scientific). The ex vivo expanded
primary epithelial and mesenchymal stromal cells were characterized by
immunocytochemical and flow cytometric analyses on the expression of epithelial
markers, such as E-cadherin and Pan-cytokeratin and MSC markers, such as
CD90 and CD105, respectively. In this study, the AM primary cells following≥ six
passages appeared to become differentiated and lost their propagating ability.
Primary cells at early passages were cryopreserved, and cells less than six
passages were used for further experiments. Previous studies have shown the
difference between primary cells and cell lines, and cell lines may undergo
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chromosomal rearrangements/duplications or mutations, and epigenetic changes
that make cell lines could not recapitulate the primary tumor behaviors 51,52.
Therefore, most experiments were performed by using primary AM cells.

2.4 Immunohistochemical (IHC) and immunofluorescence (IF)
studies
The human tumor samples were fixed in 4% paraformaldehyde (Santa Cruz)
for overnight at 4C and embedded in either paraffin or Optimal Cutting
Temperature (OCT) Compound. For IHC staining, paraffin-embedded sections
were deparaffinized, unmasked with Antigen Unmasking Solution, Citric Acid
Based (Vector) for twenty minutes at 95C and followed by the protocol of avidinbiotin complex (ABC) kit (VECTASTAIN ABC Kit, Vector). Briefly, sections were
incubated at 4C overnight with primary antibodies for human LGR5 (Invitrogen,
PA5-35304) or BRAF V600E (Invitrogen, MA5-24661). Next day, VECTASTAIN
ABC Kit were applied to the sections, followed by color development using
VECTOR NovaRED Peroxidase (HRP) Substrate Kit (Vector) and counterstained
with hematoxylin. Isotype-matched control antibodies (BioLegend) were used as
negative controls. Images were observed and photographed under a microscope
(Olympus,

IX73).

Immunohistochemistry

results

were

evaluated

by

a

semiquantitative approach, H-score (“histo” score). Traditional H-score is based
on the staining intensity (0=negative; 1=weak; 2=moderate; 3=intense) for each
cell in a fixed field and calculated by the formula: [1 × (% cells of intensity 1) + 2
× (% cells of intensity 2) + 3 × (% cells of intensity 3)] to get the final score,
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ranging from 0 to 30053. In this study, a digital quantification of H-Score was
analyzed by Color Deconvolution of ImageJ software54. Briefly, each staining was
observed and captured at least 3 fields by a microscope. Then each image was
processed by “color deconvolution” using the “vector HDAB”, where the staining
of hematoxylin and diaminobenzidine (DAB) was separated into 3 different
panels: hematoxylin, DAB and background. Next, the area of epithelium or
stroma in the DAB image was randomly selected, and the selected area were
analyzed by “histogram”, which calculated the mean intensity of DAB in area
(mm2), ranging from 0 (black) to 255 (total white). Finally, the H-score was
counted by subtracting the mean intensity of DAB from 255.
For dual-color immunofluorescence (IF) study, frozen sections were
permeabilized in 0.5% triton X-100 in PBS for 15min and then blocked in 2.5%
goat serum in PBS at room temperature for 1h, followed by incubation at 4C
overnight with a primary antibody for LGR5 (ORIGENE, TA503316, mouse IgG;
or Invitrogen, PA5-35304, rabbit IgG) in combination with another primary
antibody derived from a different host species, including Pan-Cytokeratin
(BioLegend, 914204), ALDH1 (BD Biosciences, 611194), OCT4 (Abcam,
ab18976), ZEB-1 (Santa Cruz, sc-25388), non-phospho (Active) β-catenin (Cell
Signaling, 8814S), fibronectin (Sigma, F3648), human mitochondria (Novus, 1131) and PCNA (Santa Cruz, sc-7907). Afterwards, the sections were incubated at
room temperature for 1 h with appropriate fluorochrome-conjugated secondary
antibodies: DyLight™ 488 Donkey anti-rabbit IgG, Alexa Fluor 594 Donkey anti25

rabbit IgG, DyLight™ 488 Goat anti-mouse IgG, and Alexa Fluor 594 Goat antimouse IgG (BioLegend). Isotype-matched control antibodies (BioLegend) were
used as negative controls. Nuclei were counterstained with 4, 6-diamidino-2phenylindole (DAPI) Staining Solution (Abcam) and images were captured with
Olympus inverted fluorescence microscope (IX73). Correlation coefficient of dualcolor IF study was calculated by CellProfiler software (Appendix III)55. Briefly, a
pixel-based method was used and all pixels in an image were determine between
the channels. Then the linear Pearson correlation coefficient between the two
channels was computed by the slope a of the line y=ax +b, where y and x are the
two channel intensities, indicating the overall relative intensity of the two
channels.

2.5 Immunocytochemical studies
Cultured cells in eight-well chamber slides (Millicell EZ SLIDES) were fixed
with cold methanol for 15 minutes at -20C. Then cells were incubated with the
following primary antibodies at 4C overnight: β-catenin (Cell Signaling, 8480S),
active β-catenin (Cell Signaling, 8814S), cyclin A (Sigma, C4710), cyclin B
(Sigma, C8831), cyclin D1 (Cell Signaling, 2926), and cyclin E (Cell Signaling,
4129). The cells were then incubated with appropriate fluorochrome-conjugated
secondary antibodies as described above. Isotype-matched control antibodies
were used as negative controls. Nuclei were counterstained with DAPI Staining
Solution and then images were captured using Olympus inverted fluorescence
microscope (IX73). For quantitative analysis of mean fluorescence intensity (MFI),
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cells with positive signals in at least six random fields were measured by
Olympus cellSens software.

2.6 Flow cytometry
AM epithelial cells were harvested and suspended in cell staining buffer
(0.5% BSA in PBS with 2mM EDTA) followed by incubation with primary antibody
for LGR5 at 4C for 30 min. After washing with PBS, the cells were incubated
with appropriate fluorochrome-conjugated secondary antibody in the dark at 4C
for 30 min. Following immunostaining of the cell surface LGR5, the cells were
fixed and permeabilized using True-Nuclear™ Transcription Factor Buffer Set
(BioLegend) and then immunostained with a specific antibody for OCT4 (Abcam,
ab18976), followed by staining with a fluorescein-conjugated secondary antibody.
Isotype-matched IgG control antibodies were used as negative controls. ALDH
activity was identified by a non-immunological method (ALDEFLUOR Kit,
STEMCELL) and the inhibitor of ALDH enzyme (ALDEFLUOR DEAB Reagent,
STEMCELL) was used as negative controls. Samples were analyzed by BD
LSRII flow cytometer. Data were processed and analyzed by FlowJo software.

2.7 Cell proliferation assay
AM epithelial cells were seeded into 96-well culture plates in a density of
1x104 cells/well in 100 µl of defined KGM-2 medium with five independent
replicates per treatment condition. 24 h later, the cells were washed once with
PBS and starved in Keratinocyte basal Medium 2 (KBM2, Lonza) overnight. Then
R-spondin 1 (Rspo1, PeproTech) and Rspo2 (PeproTech) were administrated to
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the starved AM epithelial cells at concentrations of 0, 5, 10, and 20 ng/ml,
respectively. After 72 h, 10 µl of CCK-8 reagent (Cell Counting Kit-8 assay,
BioLegend) was added into each well and incubated at 37 °C for 2 h. The
absorbance at 450 nm wavelength was detected using an OPSYS Mr microplate
reader (Thermo Fisher).

2.8 Cell cycle analysis
AM epithelial cells were seeded into 35-mm culture dishes at a density of
3x105 cells per dish containing 2ml of defined KGM-2 medium. 24h later, the
cells were washed once with PBS and starved in basal KBM2 medium overnight.
Then 20 ng/ml Rspo2 were administrated to the starved AM epithelial cells while
nontreated cells were used as the control. Both control and Rspo2-stimulated
cells were labelled with Bromodeoxyuridine (BrdU) Labeling Reagent (Invitrogen)
overnight and then harvested after stimulation with Rspo2 for 48h. Cells were
then fixed with 70% cold ethanol for 2h and permeabilized in 2 N HCl/0.5% Triton
X-100 at room temperature for 30min. Then, the cell pallet was treated with 0.1 M
sodium tetraborate (pH8.5) for 2 min followed by washing twice with PBS.
Afterwards, cells were incubated with a specific mouse monoclonal IgG for BrdU
(Sigma, B8434) at room temperature for 1h followed by incubation with DyLight™
488 Goat anti-mouse IgG at room temperature for 30 min. After washed cells
with PBS, the pellet was resuspended in 0.5 ml PBS containing 10 μg/ml RNase
A and 20 μg/ml propidium iodide (PI) solution and incubated at room temperature
for 30 min in the dark. The samples were analyzed by BD LSRII flow cytometer
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immediately. Data were processed and analyzed by FlowJo software.

2.9 Western blot
Cell lysates were prepared by incubation with radioimmunoprecipitation
(RIPA) assay buffer (Santa Cruz) supplemented with a cocktail of protease
inhibitors (Santa Cruz) and the total protein concentrations were determined
using bicinchoninic acid (BCA) method (BioVision). Then 30µg of total proteins
were subjected to SDS-polyacrylamide gel electrophoresis before being
electroblotted onto a 0.2 μm nitrocellulose membrane (GE Healthcare). After
blocking with 5% nonfat dry milk in TBST [25 mmol/L Tris (pH, 7.4), 137 mmol/L
NaCl, 0.5% Tween20], membranes were incubated at 4°C overnight with
following primary antibodies: LGR5 (Invitrogen, PA5-35304), ALDH1 (BD
Biosciences, 611194), OCT4 (Abcam, ab18976), β-catenin (Cell Signaling,
8480S), Active β-catenin (Cell Signaling, 8814S), cyclin A (Sigma, C4710), cyclin
B (Sigma, C8831), cyclin D1 (Cell Signaling, 2926) and cyclin E (Cell Signaling,
4129), ZEB-1 (Santa Cruz, sc-25388), fibronectin (Sigma, F3648) and ECadherin (BD Biosciences, 562869). β-actin (Santa Cruz, sc-47778) was used as
loading control. After extensively washing, membranes were incubated with
horseradish peroxidase (HRP)–conjugated secondary antibodies (Santa Cruz)
and blot signals were developed with ECLTM Western Blotting Detect Reagents
(GE Health Care).

2.10 Cell sorting
LGR5+ AM epithelial cells were sorted by using magnetic Anti-LGR5
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MicroBeads (Miltenyi Biotec) according to the manufacturer’s protocol. Briefly,
cultured AM epithelial cells were labeled with Anti-LGR5 MicroBeads at 4°C for
15 min. After washing, the cell suspension was applied to a LS Colum and
separated with a magnetic MACS Manual Separator (Miltenyi Biotec). The purity
of sorted LGR5- and LGR5+ AM epithelial cells was examined by flow cytometry
and confirmed by Western blot with a LGR5 antibody (Invitrogen, PA5-35304).

2.11 Spheroid formation assay
3D-spheroid formation assay was performed as described previously 56-58.
Brieﬂy, unsorted (parental), sorted LGR5- and LGR5+ AM epithelial cells were
seeded at a density of 5×104 cells/well into Ultralow attached 6-well plates
(Corning) with defined serum-free KGM-2 medium (n=3). For 3D-spheroid culture
in Matrigel, parental, 5×105 of sorted LGR5- and LGR5+ AM epithelial cells were
suspended in 10μl KGM-2 medium, mixed with 40μl Matrigel (Corning), and
seeded in 24-well plates with defined serum-free KGM-2 medium (n=3). After
culturing for 2 weeks, each sample was observed and captured randomly (n=8)
by Olympus microscope (IX73). Then spheroids with a size larger than 20μm
were counted, and the size and number of spheroids were measured with
Olympus cellSens software. To prepare the spheroids in Matrigel for IF study, the
whole Matrigel containing spheroids was fixed in 4% PFA for 15 min followed by
washing twice with PBS for 15 min each time. The spheroids with Matrigel were
detached from the dish by a fine flat spatula and transferred to the mold. The
whole Matrigel contained spheroids were embedded in OCT and frozen sections
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at 10µm were cut for IF study.

2.12 Cell migration assay
Migration assay was performed by using 8μm permeable cell culture inserts
in 24-well plate (CELLTREAT 230633) according to the manufacturer’s protocol.
The parental AM-1 cells were starved in KBM2 overnight and then sorted by
magnetic Anti-LGR5 MicroBeads. The sorted LGR5 negative and positive AM-1
cells were seeded into the upper chambers of trans-wells (7x104 cells/well) with
200μl basal KBM2 medium and the lower chambers were filled with 600μl
defined KGM-2 culture medium (n=3 for each group). After 16 hours, the transwells were gently washed with PBS twice and non-migrated cells were removed
with cotton rods. Then the migrated cells on trans-wells were fixed with 70%
ethanol for 10 min and dried for 10-15 min. The migrated cells were stained by
0.5% crystal violet in room temperature for 10 min and then gently washed with
PBS. After air dry overnight, the migrated cells were photographed and counted
under the microscope.

2.13 Preparation of AM-MSC derived conditioned medium/
secretomes
The AM-MSCs were culture in complete α-MEM. When cells reached 80%
conﬂuence, the cells were washed with PBS twice and then cultured in serum
free α-MEM for 48 hours. After 48 hours, the culture medium of AM-MSC were
collected and centrifuged at 4,400 rpm for 20 min to remove the cell debris. Then
the supernatant was collected and concentrated by 30 kDa ultra centrifugal filter
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unit (Millipore) at 4,400 rpm about 30 min twice with one wash with PBS between
the two centrifuges to 100X concentrated medium. Then the protein
concentration of AM-MSC derived conditioned medium was determined by
bicinchoninic acid (BCA) assay (BioVision).

2.14 3D-organoids derived from AM epithelial cells
Single-cell suspensions of AM epithelial cells were directly dispersed into
Growth Factor Reduced (GFR) Matrigel (Corning Life Sciences) at a density of
2×104 cells/μl (~1x106 each group) and seeded in a drop shape. The dish was
inverted during solidification of Matrigel to prevent the cells attaching to the
culture dish. After solidified for 20 minutes, the mixture of the cells and Matrigel
were cultured in AM-organoid culture medium: 50% KGM2 and 50% Dulbecco's
Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12, Thermo Fisher). The
organoid formation was observed under a microscope every 2-3 days and the
whole Matrigel containing organoids was harvested on day 10. To prepare the
Matrigel for frozen section, the gel was washed with PBS twice, and the whole
Matrigel including organoids was fixed in 4% PFA for 15 minutes following by
washing with PBS twice for 15 minutes each time. The organoids with Matrigel
were detached from the dish by fine flat spatula and transferred to the mold. The
whole Matrigel contained organoids was embedded in OCT for frozen section.
Both H & E staining and immunofluorescence studies on the expression of PanCytokeratin, LGR5 and active β-catenin were performed.
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2.15 3D-organoids derived from AM epithelial cells and AMMSCs
Single-cell suspensions of AM epithelial cells and AM-MSCs (with or without
green fluorescent protein, GFP, lentivirus transduction) (cell ratio: 2:1) were
directly dispersed into Matrigel at a density of 4×104 cells/μl (~1.5 x 106 each
group) and seeded in a drop shape. The dish was inverted during solidification of
Matrigel to prevent the cells attaching to the culture dish. After solidified for 20
minutes, the mixture of the cells and Matrigel were cultured in AM-organoid
culture medium 2: 50% KGM2 and 50% Dulbecco's Modified Eagle
Medium/Nutrient Mixture F-12 (DMEM/F12, Thermo Fisher), and supplemented
with 10 ng/ml EGF, 20 ng/ml FGF and 0.5X Insulin-Transferrin-Selenium (Thermo
Fisher). The organoid formation was observed under a microscope every day
and the whole Matrigel containing organoids was passaged or cryopreserved on
day 4. Briefly, after washing with PBS twice, the whole Matrigel containing
organoids was broken down by 1000ul pipet tip and collected with 500ml iced 1%
BSA in PBS to a 1.5 ml centrifuge tube. Then, spin down at 1,500 rpm for 5 min
and carefully remove the supernatant. The pellet was dissociated with 400ml 1×
Accutase solution in 37C for 20-30 min, and washed with 1% BSA twice. The
dissociated cells were directly dispersed into Matrigel at a density of 4×10 4
cells/μl

or

into

the

cryopreservation

media

followed

by

the

normal

cryopreservative procedure. The frozen organoid cells were thawed, washed and
directly dispersed into Matrigel followed the same culture procedure. The
preparation of the organoids in Matrigel for frozen section is same as AM33

organoids derived from AM epithelial cells. Both H & E staining and
immunofluorescence studies on the expression of E-cadherin (24E10, Cell
Signaling Technology), CD90 (5E10, BioLegend), vimentin (sc-32322, Santa
Cruz Biotechnology) and LGR5 (ORIGENE, TA503316, mouse IgG; or Invitrogen,
PA5-35304, rabbit IgG) were performed.

2.16 Subcutaneous transplantation of AM 3D-Organoids into
nude mice
Eight-week-old female and male athymic NU/J mice were purchased from
Charles River Laboratory. All animal procedures were handled according to the
guidelines of the Institutional Animal Care and Use Committee of (IACUC) at
University of Pennsylvania. Mice were group-housed in polycarbonate cages
(five animals per cage) in the animal facility with controlled temperature, 40%65% of humidity and a 12-hour light/dark cycle. Mice were acclimatized for at
least 1 week before the study, fed with a standard laboratory diet and allowed ad
libitum access to drinking water. For subcutaneous transplantation, nude mice
were randomly assigned into six groups transplanted with 8×10 5 AM-EpiCs
(parental, sorted LGR5- and LGR5+) and 8×105 AM-EpiCs + AM-MSCs with 1:1
cell ratio (parental + MSCs, sorted LGR5- + MSCs and LGR5+ +MSCs),
respectively. Cells were pre-cultured in Matrigel for three weeks and then
subcutaneously implanted into the dorsal skin of nude mice (n=3-4 in each
group). Two to four weeks after transplantation, xenografted tumors were
harvested for histologic analysis and IF studies on the expression of LGR5,
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human mitochondria, PCNA, EMT- and stem cell-related genes. No blinding was
carried out for animal experiments.
For cell-dilution assay, we sorted LGR5+ cells from parental primary AM
epithelial cells and AM-1 cells and then cultured in Matrigel (50μl) for two weeks
with different cell numbers: 103, 104, 105 and 106 (n=2 in each group). After two
weeks, the organoids in Matrigel were transplanted subcutaneously into the
dorsal skin of nude mice. 4-weeks post-transplantation, the volume of
transplanted organoid xenografts was calculated; the histology was examined by
H & E staining, and the expression of human LGR5 and PCNA was determined
by IF studies.

2.17 Statistical analysis
All data are presented as mean ± SD and analyzed using unpaired Student’s
t-test for comparing two groups when appropriate. In cases of multiple groups,
statistical analysis was performed through one-way ANOVA analysis with Tukey
post-test. Fisher’s exact test and Chi-square teat were used to compare
proportions in one or more categories. All analyses were done using GraphPad
Prism. A value of P<0.05 was considered to be statistically significant.
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CHAPTER 3: RESULTS
3.1 LGR5 is highly expressed in epithelial cells in AM tissues
LGR5 has been reported as a stem cell marker in multiple normal and
malignant tissues and recent studies revealed that LGR5+ CSCs promote EMT
process and are essential for tumor metastasis34,35. Our recent studies have
identified a subpopulation of AM epithelial cells with increased expression of both
stemness- and EMT-related markers upon co-culture with AM-MSCs24. Herein, I
further explored whether LGR5 represented a putative marker for epithelial stemlike cells in AM. To this purpose, the expression of LGR5 in a total of fifteen
human AM tissues (ten follicular type; two plexiform type; three desmoplastic
type) versus corresponding normal adjacent tissues (NATs), and six benign
odontogenic cysts (OC) was initially evaluated. The results from IHC studies
showed that LGR5 expression was consistently higher in different histological
variants of solid AM (follicular, plexiform, and desmoplastic AM), as compared to
OCs, and the corresponding NATs (Figure 3.1 A-C). Of note, the overall H-score
of LGR5 expression in AM tumor tissues was much higher, 4-fold, than that in
normal control and OCs (Figure 3.1 C). The immunoreactive signals of LGR5
expression are mainly localized in the AM epithelial islands, with an average
70.45% of LGR5+ cells in epithelial islands versus an average 18.62% of LGR5 +
cells in stroma of the total fifteen AM tissues (Figure 3.1 D and E). The
expression of LGR5 in AM epithelial islands was slightly higher in the plexiform
(85.98%) than that in the follicular type (66.50%) (p< 0.05).
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Figure 3.1 LGR5 is highly expressed in epithelial cells in AM tissues. A The
paraffin-embedded sections of odontogenic cyst (OC) were processed for IHC staining
with a specific antibody for human LGR5 (n=6). Scale bars, 50μm. NAT: normal adjacent
tissue (same patient). B Expression of LGR5 in different histopathological types of AM
(n=15). Scale bars, 20μm. NAT: normal adjacent tissue (same patient). C The
quantification of H-score of LGR5 expression in AM (n=15) and odontogenic cyst (OC)
(n=6). H-Score of each sample was analyzed at least 9 different areas by Color
Deconvolution of ImageJ software and data are mean ± SD. Two-tailed unpaired
Student’s t-test. ****p<0.0001. D The quantification of H-score of LGR5 expression in
stroma and epithelial islands of AM, respectively. Data are mean ± SD. Two-tailed paired
Student’s t-test. ****p<0.0001. E Relative percentage was converted from the H-Score
values in (D). The immunoreactive signals of LGR5 expression are mainly localized in
the AM epithelial islands, with an average 70.45% of LGR5+ cells in epithelial islands
versus an average 18.62% of LGR5+ cells in stroma of the total fifteen AM tissues. HScore of each sample was analyzed at least 5 different areas by Color Deconvolution of
ImageJ software and data are mean ± SD.
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3.2 Characterization of a subpopulation of LGR5+ stem-like
epithelial cells in AM
This study then determined whether LGR5 expression was associated with
other stem cell-related genes in solid type of AM tissues. Dual-color
immunofluorescence study showed that about 66.3% of LGR5 signal was colocalized with the pan-cytokeratin (Pan-CK) in AM tissues, indicating that LGR5
was mainly expressed by epithelial cells in AM (Figure 3.2). Since the solid type
of AM accounts for about 80% of all AM cases and has a high recurrence rate 1,59,
this study focused on this major type of AM. Dual-color immunofluorescence
studies showed that within the epithelial islands of all three subtypes of solid type
of AMs, LGR5 was simultaneously expressed with aldehyde dehydrogenase 1
(ALDH1) and octamer-binding transcription factor 4 (OCT4) (Figure 3.2 A, C and
D), two well-recognized stem cell-regulatory genes identified in CSCs of multiple
cancers60-63. Further analysis indicated that about 68.6% of LGR5+ epithelial cells
simultaneously

expressed

ALDH1

and

74.1%

LGR5 +

epithelial

cells

simultaneously expressed OCT4 (Figure 3.2 B). These results suggest that solid
type of AM tissues harbor a subpopulation of LGR5 + epithelial cells expressing
stem cell-related genes.
To characterize the stem cell properties of the subpopulation of LGR5 +
epithelial cells in AM, primary epithelial cells derived from solid follicular AM
tissues (AM epithelial cells), as previously described 24 (Figure 3.3 A),

were

cultured under 3D-spheroid forming condition, an approach utilized for selfrenewal and enrichment of stem cells64-67. The results showed that expression of
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LGR5, ALDH1, and OCT4 was significantly increased in AM epithelial cells after
5 days in 3D-spheroid culture, as compared to those under 2D culture condition
(Figure 3.3 B and C). Flow cytometric analysis showed that LGR5 + cells grown in
3D-spheroid condition were consistently enriched by three-fold (from 9.95 ± 3.43
% to 27.1 ± 6.52 %) as compared to 2D culture (Figure 3.4 A). Meanwhile,
LGR5+OCT4Low, LGR5+OCT4High, and total OCT4High cells in AM epithelial cells
were further analyzed. The results showed that under 3D-culture versus 2Dculture, both LGR5+OCT4Low and LGR5+OCT4High cells were significantly
enriched, from 3.98% to 21.8% and 2.09% to 14.7%, respectively; and total
OCT4High cells were increased from 10.11% to 23.64% (Figure 3.4 B). In addition,
ALDH1 activity increased about three-fold in AM epithelial cells in 3D-spheroid
versus 2D cultures by evaluating ALDH activity using ALDEFLUOR assay
(Figure 3.4 C). Similarly, LGR5+ and LGR5+OCT4High cells were enriched while
ALDH1 activity increased in immortalized AM-1 cells when cultured under 3Dspheroid culture condition (Figure 3.5). Collectively, these results suggest that
LGR5+ALDH1+OCT4High AM epithelial cells may have self-renewal capability and
represent a subpopulation of tumor epithelial stem-like cells in solid AM (AMEpiSCs).
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Figure 3.2 Simultaneous expression of LGR5 and certain stem cell-related markers
in AM tissues. A Left: dual-color immunofluorescence study showed that simultaneous
expression of LGR5 and Pan cytokeratin (PanCK), ALDH1 and OCT4 in the follicular
tissue, respectively. Scale bars, 20μm. B The quantification of correlation coefficient of
LGR5 and epithelial biomarker (PanCK) and stem cell-related markers (ALDH1 and
OCT4) in the solid AMs (n=3). The results showed that about 66.3% of LGR5 signal was
simultaneously expressed with the expression of PanCK in the solid AM tissues. About
68.6% and 74.1% of LGR5+ cells simultaneously expressed ALDH1 and OCT4,
respectively. Each group was calculated at least three different areas by CellProfiler
software and data are mean ± SD.
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Figure 3.2 Cont’d. C Dual-color immunofluorescence study showed that simultaneous
expression of LGR5 and PanCK, ALDH1 and OCT4 in the plexiform tissue, respectively.
Scale bars, 20μm. D Dual-color immunofluorescence study showed that simultaneous
expression of LGR5 and PanCK, ALDH1 and OCT4 in the desmoplastic tissue,
respectively. Scale bars, 20μm.
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Figure 3.3 LGR5+ALDH1+OCT4High AM epithelial cells are enriched in 3D-spheroid
culture. A Morphology of AM epithelial cells derived from primary human AM tissues
and cultured under 2D-monolayer or 3D spheroid-forming conditions. Scale bars, 100μm.
B AM epithelial cells were cultured under 2D-monolayer or 3D-spheroid culture
conditions for 5 days. The simultaneous expression of LGR5, ALDH1, and OCT4 was
observed by immunofluorescence studies. Scale bars, 20μm. C Augmented expression
of LGR5, ALDH1, and OCT4 in AM epithelial cells under 3D-spheroid culture versus 2Dmonolayer culture as determined by Western blot analysis. All results are representative
of at least three independent experiments.
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Figure 3.4 LGR5+ALDH1+OCT4High AM epithelial cells are enriched in 3D-spheroid
culture. A About three-fold enrichment of LGR5+ AM epithelial cells (from 6.79% to
21.2%) under 3D-spheroid culture versus 2D-monolayer culture as determined by flow
cytometric analysis. B The proportion of LGR5+OCT4Low, LGR5+OCT4High, and total
OCT4High cells in AM epithelial cells cultured under 2D-monolayer culture and 3Dspheroid conditions was determined by flow cytometry. C The activity of ALDH1 was
increased by about three-fold (4.4% to 11.8%) in AM epithelial cells under 3D-spheroid
culture versus 2D-monolayer culture as determined by flow cytometric analysis. All
results are representative of at least three independent experiments.
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Figure 3.5 LGR5+ALDH1+OCT4High are enriched in AM-1 cells under 3D spheroidforming culture conditions. A Flow cytometric analysis showed that LGR5+ cells were
enriched by about two-fold (from 29.4% to 55.5%) in AM-1 cells under 3D-spheroid
culture for 5 days. Red: LGR5. Gray: negative control. B The proportion of
LGR5+OCT4Low, LGR5+OCT4High, and total OCT4High cells in AM-1 cells cultured under
2D-monolayer culture and 3D-spheroid conditions was determined by flow cytometry. C
The ALDH1 activity was increased by about three-fold (3.75% to 13.1%) in AM-1 cells
under 3D-spheroid culture for 5 days. All results are representative of at least three
independent experiments.
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3.3 LGR5+ AM epithelial cells are endowed with intermediate
EMT phenotype and stem cell properties in vitro
The stem cell properties of LGR5+ AM epithelial cells were then further
characterized. To this end, LGR5+ AM epithelial cells were sorted from parental
primary AM epithelial cells using LGR5 antibody-conjugated with magnetic beads
and confirmed by flow cytometry (Figure 3.8 A). 3D-spheroid forming assay
under suspension culture conditions showed that LGR5+ AM epithelial cells
formed more abundant and larger spheroids than LGR5- counterparts (Figure 3.6
A and B). Meanwhile, sorted LGR5+ AM epithelial cells when cultured in 3D
extracellular matrix (ECM) Matrigel for two weeks also readily formed larger 3Dspheroids as compared to LGR5- counterparts (Figure 3.6 C and D). Similarly,
LGR5+ cells sorted from AM-1 cells also exhibited increased 3D-spheroid forming
capability as compared to the LGR5- counterparts (Figure 3.8 B and C). These
results suggest that LGR5+ AM epithelial cells are more capable of self-renewal
than their LGR5- counterparts.
Since EMT contributes to cell plasticity and cancer stem cell (CSC)
formation22, the expression profiles of stem cell-related and EMT-regulatory
transcriptional factors (TFs) in sorted LGR5+ and LGR5- AM epithelial cells were
then compared. Western blot analysis demonstrated an increase in the
expression of stem cell-related markers, ALDH1 and OCT4, as well as EMTrelated markers, ZEB1, active β-catenin (ABC) and fibronectin, in LGR5+ cells
sorted from both primary AM epithelial cells and AM-1 cell lines in comparison
with their LGR5- counterparts, respectively (Figure 3.6 E and Figure 3.8 D).
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Additionally, the simultaneous expression of LGR5 and ZEB1, ABC, and
fibronectin was further confirmed in different subtypes of solid AM tissues as
determined by immunofluorescence studies (Figure 3.6 F and Figure 3.7).
Functionally, LGR5+ AM epithelial cells exhibited significantly increased migration
ability as compared to their LGR5- counterparts (p<0.001) was found (Figure 3.8
E and F). Taken together, these findings suggest that LGR5 + epithelial cells also
possess features characteristic of an intermediate EMT phenotype.
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Figure 3.6 LGR5+ AM epithelial cells exhibit self-renewal ability and EMT
phenotypes. A and B LGR5+ AM epithelial cells were sorted out from parental primary
AM epithelial cells using LGR5 antibody-conjugated magnetic beads, which showed
increased 3D spheroid-forming ability than their LGR5- counterparts (n=3). Scale bars,
50μm. Data are Mean ± SD (each group was measured 8 different random areas under
the microscope), two-tailed unpaired Student’s t-test. *** p<0.001, **** p<0.0001. C
Sorted LGR5+ AM epithelial cells formed more and larger 3D-spheroids as compared
with LGR5- counterparts after culturing in 3D extracellular matrix (ECM) Matrigel for two
weeks (n=3). Scale bars, 20μm. D The quantification of spheroid formation as shown in
(C). Data are Mean ± SD (each group was measured 3 different random areas under the
microscope), two-tailed unpaired Student’s t-test. *** p<0.001, **** p<0.0001. E
Increased expression of stem cell-related markers, ALDH1 and OCT4, and EMT related
markers, ZEB1, active β-catenin (ABC) and fibronectin (FN), in sorted LGR5+ AM
epithelial cells as compared to that in LGR5- counterparts. F Simultaneous expression of
LGR5 and specific EMT related markers, ZEB1, ABC and FN in the follicular AM tissue.
Scale bars, 20μm. All results are representative of three independent experiments.
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Figure 3.7 Simultaneous expression of LGR5 and certain EMT-related genes
expressions in AM tissues. A and B Simultaneous expression of LGR5 and specific
EMT related markers, ZEB1, ABC and fibronectin (FN) in the plexiform (A) and
desmoplastic (B) AM tissues as determined by immunofluorescence studies. C The
quantification of the results shown in (A and B), and Figure 3.6 F (follicular type). n=3,
each group was calculated at least three different areas by CellProfiler software and
data are mean ± SD. Scale bars, 20μm.
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Figure 3.8 LGR5+ AM-1 cells exhibit self-renewal ability. A About 90% of sorted
LGR5+ AM epithelial cells was positive for LGR5 as confirmed by flow cytometric
analysis. B Sorted LGR5+ AM-1 formed larger 3D-spheroids than those by LGR5counterparts following cultured in 3D Matrigel for two weeks. Scale bars, 100μm. C The
quantification of the results shown in (B). Data are Mean ± SD (each group was
measured 3 different random areas under the microscope), Two-tailed unpaired
Student’s t-tests. ***p<0.001. D Increased expression of stem cell-related markers,
ALDH1 and OCT4, and EMT related markers, ZEB1, active β-catenin (ABC) and
fibronectin in sorted LGR5+ AM-1 cells in comparison to that in LGR5- counterparts as
determined by Western blot analysis. E The sorted LGR5- and LGR5+ AM-1 (7x104
cells/well in 200μl basal KBM2 medium) were seeded onto the upper chamber of 24transwells and the lower chambers were filled with 600μl defined KGM-2 culture medium
(n=3 for each group). After culture overnight (16h), the migrated cells were stained with
crystal violet and images were taken under a microscope. Scale bars, 100μm. F The
quantification of the results shown in (E). Data are Mean ± SD (each trans-well was
measured 6 different random areas under the microscope with 100x magnification),
Two-tailed unpaired Student’s t-tests. **p<0.01. All results are representative of at least
two to three independent experiments.
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3.4 LGR5/R-spondin stimulates proliferation and EMT/ stemness
markers of AM epithelial cells
R-spondin 1 to 4 (Rspo1-4), four secreted Wnt agonists, can activate the
canonical Wnt pathway through binding with their endogenous LGR receptor
family members, LGR4, LGR5 and LGR625,68. The biological function of LGR5
was then determined by stimulating AM epithelial cells with its ligands, Rspondin-1 or -2 (Rspo1 and Rspo2). To this purpose, primary AM epithelial cells
were stimulated with Rspo1 and Rspo2 for 48h, respectively, and the proliferative
activity was evaluated. The results showed that stimulation with either Rspo 1 or
Rspo2 led to a dose-dependent increase in the proliferation in AM epithelial cells
(Figure 3.9 A). Western blot analysis showed that treatment with Rspo1 and
Rspo2 significantly increased the expression of active β-catenin (ABC), cyclin A,
D1 and E in AM epithelial cells, while the stimulatory effect conferred by Rspo2
was more robust than that by Rspo1 (Figure 3.9 B). The increased expression of
ABC, cyclin A, D1 and E in nuclei of AM epithelial cells following treatment with
Rspo2 for 48h was further confirmed by immunofluorescence (IF) studies (Figure
3.9 C and D). Similarly, stimulation with Rspo2 increased the expression of ABC,
cyclin A, D1 and E as well as the percentage of cells at S-phase (from 8.27% to
12.4%) in AM-1 cells (Figure 3.10 A and B). Of note, Rspo2 upregulated the
expression of OCT4 and fibronectin but decreased the expression of E-cadherin
in AM-1 cells (Figure 3.10 C). Meanwhile, ameloblastoma epithelial cells showed
significantly enhanced 3D-spheroid forming capacity upon exposure to Rspo 2 as
compared to the control (vehicle) group (Figure 3.10 D). These findings suggest
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that functional LGR5/R-spondin may contribute to AM tumor growth through
promoting proliferation, EMT, and acquisition of stem cell properties in AM
epithelial cells.
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Figure 3.9 AM epithelial cells are responsive to R-spondin stimulation. A
Stimulation with R-spondins (Rspo1 and Rspo2) for 72h increased proliferation in AM
epithelial cells in a dose-dependent manner. Mean ± SD, n=5, one-way ANOVA and
Dunnett’s post-test for comparing treatments to untreated control. Control=PBS. NS=not
significant. *p<0.05, **p<0.01, ***p<0.001. B Stimulation with R-spondins (Rspo1 and
Rspo2) for 48h increased the expression of active β-catenin (ABC), cyclin A, D1, and E
in AM epithelial cells in a dose-dependent manner as determined by Western blot
analysis. C Stimulation with 20ng/mL of Rspo2 for 48h increased the expression of
active β-catenin (ABC), cyclin A, D1, and E in nuclei of AM epithelial cells as determined
by immunofluorescence studies. Scale bars, 20µm. D The quantification of the results
from immunofluorescence studies shown in (C). MFI: mean fluorescence intensity. Each
group was measured 6 different random areas and data are mean ± SD. Two-tailed
unpaired Student’s t-tests, NS=not significant, **p<0.01, ***p<0.001. All results are
representative of three independent experiments.
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Figure 3.10 R-spondin stimulation promotes proliferation, EMT-related markers
and self-renewal ability of AM-1. A The stimulation with Rspo2 for 48 h increased the
expression of active β-catenin (ABC), cyclin A, D1 and E in AM-1 cells in a dosedependent manner. B Flow cytometry showed increased proportion of AM-1 cells at Sphase after stimulation with Rspo2 (20ng/ml) for 48 h. C Stimulation with of Rspo2 for
48h led to a dose-dependent increase in the expression of OCT4 and fibronectin but
decreased the expression of E-cadherin in AM-1 cells as determined by Western blot
analysis. D Stimulation with of 20ng/mL of Rspo2 for 10 days significantly increased 3Dspheroid formation in AM-1 cells as compared with the control group. Mean ± SD, twotailed unpaired Student’s t-test (n=3 in each group). ****p<0.0001.
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3.5 Generation of ex vivo AM three-dimensional organoid model
with AM epithelial cells
In recent years, several progresses have been made in the development of
novel 3D organoid models for a variety of cancers, to study tumorigenesis,
cancer stem cell biology, tumor microenvironment, and drug screening, etc. 49,69-71.
Up to date, there are no experimental models to study benign tumor of jaw bone,
especially ameloblastoma. Here, I explored feasibility to generate the human AM
3D organoids as a preclinical model for this benign/aggressive tumor. To this
purpose, primary AM epithelial cells derived from follicular AM tissues or AM-1
cells (plexiform AM epithelial cell lines) were cultured in Matrigel and defined
organoid culture medium. The formation of 3D organoid-like structure by both
primary AM epithelial cells and AM-1 cells at day 2 following organoid culture
were observed (Figure 3.11 A). At day 10, the organoids were harvested for
further analysis. Histologically, the generated AM organoids recapitulated the
distinct histopathologic features of follicular and plexiform subtypes of solid AM
(Figure 3.11 B and C). Specifically, organoids generated from primary follicular
AM epithelial cells displayed hyperchromic nuclei cuboidal (ameloblast-like)
peripheral cells arranged in a palisading-like pattern and demonstrated reverse
polarity (Figure 3.11 B); while organoids generated from AM-1 cells (plexiform
type) exhibited irregular epithelial islands connected as anastomosing strands
(Figure 3.11 C). Interestingly, highly co-expression of LGR5 and active β-catenin
(ABC) was also observed in organoids generated from both primary follicular AM
epithelial cells and plexiform AM-1 cell lines (Figure 3.11 B and C), similar to that
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observed in both subtypes of solid AM tissues (Figure 3.6 F and 3.7). These
findings have demonstrated for the first time the feasibility to generate ex vivo
human AM 3D organoids, which recapitulated the histopathological features of
AM subtypes, and to further confirm the potential role of LGR5 + epithelial cells in
the pathogenesis of AM.
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Figure 3.11 3D-organoids derived from AM epithelial cells recapitulate
histopathological features of AM. A The diagram showing the generation of 3Dorganoids by AM epithelial cells. Ex vivo expanded primary AM epithelial cells or AM-1
cells were transferred to 3D Matrigel and cultured for different days. Scale bars, 20μm. B
3D-organoid culture of follicular AM epithelial cells for 10 days. Left, H&E staining
showed AM epithelial cells arranged into follicular-type organoids. AM-organoids
recapitulated certain histopathological features of AM, including hyperchromic nuclei
cuboidal (ameloblast-like) peripheral cells arranged in a palisading-like pattern and
showed reverse polarity. Right: LGR5 was simultaneously expressed with pancytokeratin and activated β-catenin (ABC) in 3D organoids formed by AM epithelial cells
as determined by immunofluorescence studies. Scale bars, 20μm. C 3D-organoid
culture of AM-1 (plexiform type) for 10 days. Left, H&E staining showed generated
organoids with irregular epithelial islands connected as anastomosing strands that were
similar to the histopathological features of plexiform AM. Right, LGR5 was
simultaneously expressed with pan-cytokeratin and activated β-catenin (ABC) in 3D
organoids formed by AM epithelial cells as determined by immunofluorescence studies.
Scale bars, left upper: 200μm; left lower and right: 20μm. All results are representative of
three independent experiments.
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3.6

Lg5+

AM

epithelial

cells

possess

self-renewal

and

propagating ability in vivo
Next, the self-renewal capability of LGR5+ AM epithelial cells in vivo was
evaluated. To this purpose, parental and sorted LGR5 + and LGR5- AM epithelial
cells were cultured in Matrigel in vitro for three weeks and then subcutaneously
transplanted into the flank of nude mice (Figure 3.12 A). At day 14 posttransplantation, histological analysis showed that parental and LGR5+ AM
epithelial cells could proliferate and generate tumor-like structures, but
transplanted LGR5- cells could not survive and were almost completely resorbed
(Figure 3.12 B), wherein the presence of human AM epithelial cells in vivo was
confirmed by immunostaining with a specific antibody for human mitochondria
(Figure 3.12 C). Meanwhile, in the tumor-like structures formed by transplanted
parental and LGR5+ AM epithelial cells, about 60% of cells simultaneously
expressed LGR5 and proliferating cell nuclear antigen (PCNA) (Figure 3.12 D).
Further analysis showed that the percentage of cells co-expressing LGR5 and
ALDH1, LGR5 and OCT4, LGR5 and ZEB1 in tumor-like structures formed by
LGR5+ AM epithelial cells was significantly higher than that in those formed by
parental AM epithelial cells (Fig. 3.13). To further evaluate the self-renewal
capability of LGR5+ AM epithelial cells in vivo, sorted LGR5+ AM epithelial cells
were cultured in Matrigel for two weeks and then performed cell-dilution assay by
subcutaneously transplanting different number of cells (106, 105, 104 and 103)
into nude mice. The results showed that one-month post-transplantation, the
implanted LGR5+ AM epithelial cells in all groups survived and exhibited
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proliferative capability (Figure 3.14). Taken together, these results suggest that
LGR5+ AM epithelial cells possess self-renewal and propagating capability in vivo.
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Figure 3.12 LGR5+ AM epithelial cells exhibit propagating ability in vivo. A The
diagram showing the subcutaneous nude mice model using ex vivo organoids. Following
culturing in 3D Matrigel for three weeks, the ex vivo organoids formed by parental,
sorted LGR5+ or LGR5- AM epithelial cells were harvested and subcutaneously
transplanted into the flank of nude mice. B Two weeks post-transplantation, the tumorlike structures formed in nude mice were harvested for histological analysis by H & E
staining. The LGR5- AM epithelial cells were mostly resorbed while the LGR5+ and
parental groups could generate some tumor-like structure. Scale bars, 20μm. C
Immunofluorescence study showed co-expression of human mitochondria and LGR5 in
xenografted tumor-like structures formed by transplanted LGR5+ and parental AM
epithelial cells, but not by LGR- counterparts. Scale bars, 50µm. D Co-expression of
LGR5 and proliferating cell nuclear antigen (PCNA) in xenografted tumor-like structures
formed by transplanted parental or LGR5+ AM epithelial cells as determined by
immunofluorescence studies (Left panels). Scale bars, 100µm. Right panel: the
quantification of relative expression of PCNA, LGR5 and PCNA/LGR5 (P/L) from the
results shown in the left panels. Mean ± SD (n=4 in each group, xenografts of AM
epithelial cells, each group was measured 5 different random areas under the
microscope, two-tailed unpaired Student’s t-test. NS=not significant).
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Figure 3.13 LGR5+ AM epithelial cells exhibit stemness and EMT markers in vivo.
Following culturing in 3D Matrigel for three weeks, the ex vivo organoids formed by
parental, sorted LGR5+ or LGR5- AM epithelial cells were harvested and subcutaneously
transplanted into the flank of nude mice. Two weeks post-transplantation, the tumor-like
structures formed in nude mice were harvested for immunofluorescence studies. A
Xenografted tumor-like structures formed by transplanted LGR5+ cells showed elevated
simultaneous expression of ALDH1 and LGR5 in comparison to those formed by
transplanted parental cells. Scale bars, 20μm. Mean ± SD, n=4, two-tailed unpaired
Student’s t-tests. *p<0.05. B Xenografted tumor-like structures formed by transplanted
LGR5+ cells showed elevated co-expression of OCT4 and LGR5 in comparison to those
formed by transplanted parental cells. Scale bars, 20μm. Mean ± SD, n=4, two-tailed
unpaired Student’s t-tests. ***p<0.001. C Xenografted tumor-like structures formed by
transplanted LGR5+ cells showed elevated simultaneous expression of ZEB1 and LGR5
in comparison to those formed by transplanted parental cells. Scale bars, 20μm. Mean ±
SD, n=4, two-tailed unpaired Student’s t-tests. *p<0.05.
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Figure 3.14 LGR5+ AM-EpiSCs exhibit self-renewal capability in vivo. For cell
dilution assay, LGR5+ cells were sorted from primary AM epithelial cells and then
cultured in Matrigel (50μl) for two weeks at different cell numbers: 103, 104, 105 and 106
(n=2 each group). After two weeks, the organoids in Matrigel were transplanted
subcutaneously into the dorsal skin of nude mice for one month. A The organoids in
Matrigel. B Organoid xenografts were harvested one-month post-transplantation. C
Calculation of the mean volume of organoid xenografts from different groups of animals.
D Histological analysis of organoid xenografts by H & E staining. Sale bars, 20μm. E The
co-expression of human LGR5 and proliferating cell nuclear antigen (PCNA) in organoid
xenografts were determined by immunofluorescence study. Scale bars, 20μm. All results
are representative of two independent experiments.
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3.7 LGR5+ AM-EpiSCs resistant to BRAFV600E inhibitor are
capable of tumor formation ex vivo
Previous studies have shown that about 46-82% of AM cases exhibit
BRAFV600E mutation

7-12.

BRAFV600E mutation in some solid type of AM tissues

was also confirmed by IHC studies (Figure 3.16 A). I next determined whether
treatment of AM-1 cells with a specific BRAFV600E inhibitor, Vemurafenib
(PLX4032), could target the subpopulation of LGR5 + cells in AM epithelial cells.
The results showed that treatment with PLX4032 reduced cell viability in a dosedependent manner (Figure 3.15 A). Interestingly, flow cytometric analysis
revealed that exposure to PLX4032 resulted in a dose-dependent enrichment of
the subpopulation of LGR5+ cells (Figure 3.15 B). Furthermore, PLX4032
apparently interfered with organoid formation, with most of the residual cells
positive for LGR5 (Figure 3.15 C and Figure 3.16 B). Western blot analysis
further confirmed that treatment with PLX4032 not only enriched LGR5
expression, but also enhanced the expression of ALDH1, OCT4, active β-catenin,
and fibronectin, and decreased the expression of E-cadherin in both primary AM
epithelial cells and AM-1 cell lines (Figure 3.17 A).
LGR5+ and LGR5- cells were sorted out from AM-1 cells following treatment
with PLX4032 and compared the expression of these stem cell- and EMT-related
genes. The results showed markedly elevated expression of ALDH1, OCT4,
active β-catenin, and fibronectin in sorted PLX4032-resistant LGR5+ cells as
compared to their LGR5- counterparts (Figure 3.17 B). Additionally, the organoidforming capacity of PLX4032-resistant LGR5+ AM-1 cells was determined. To
62

this end, AM-1 cells were treated with 20 μM of PLX4032 under 2D culture
condition for 48h. Afterwards, unsorted parental (PLX-parental), sorted LGR5+
(PLX- LGR5+) and LGR5- (PLX-LGR5-) cells were cultured in organoid culture
condition, respectively, while AM-1 cells treated with vehicle (DMSO) were used
as control (Figure 3.17 C). The results showed that PLX4032-treated AM-1 cells
(PLX-parental cells) formed significantly more and larger organoids than AM-1
cells treated with vehicle (Figure 3.17 D and E). More compellingly, LGR5 + cells
sorted from PLX4032-treated AM-1 cells (PLX- LGR5+) displayed more abundant
and larger organoids than both their LGR5 - counterparts (PLX-LGR5-) and AM-1
cells treated with vehicle (Figure 3.17 D and E). Taken together, these findings
have demonstrated that LGR5+ AM epithelial cells can surmount resistance to the
BRAFV600E inhibitor (PLX4032) and these PLX4032-resistant LGR5+ AM epithelial
cells are endowed with stem cell properties and an intermediate EMT phenotype
with enhanced capacity for tumor organoid formation.
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Figure 3.15 LGR5+ AM-EpiSCs resist BRAFV600E inhibitor in AM-organoids. A Left:
AM-1 cells were seeded on a 24 well plate in a cell density of 105/well and treated with
different concentrations of a specific BRAFV600E inhibitor (Vemurafenib, PLX4032) for 48
h (n=3). Residual cells arranged into irregular epithelial islands connected as
anastomosing strands. Right: AM-1 cells were seeded into 96-well plates (5x104
cells/well) followed by exposure to different concentrations of PLX4032 for 48 h and the
cell viability was determined by cell count kit-8. Data are Mean ± SD, n=4, two-tailed
unpaired Student’s t-test. ***p<0.001, ****p<0.0001. B Left: enriched expression of LGR5
on AM-1 cells following treatment with different concentrations of PLX4032 for 48h as
determined by flow cytometry. Right: graphs showing the results from flow cytometric
analysis as shown in the left panels. Data are Mean ± SD, n=3, two-tailed unpaired
Student’s t-test. **p<0.01. C 3D-organoids formed by AM-1 cells for 4 days were treated
with PLX4032 (20μM) for 6 days. Upper: PLX4032 interfered with 3D-organoid formation
as determined by H & E staining. Lower: the residual PLX4032-resistant AM-1 cells in
3D-organoids were positive for LGR5 as determined by immunofluorescence study.
Scale bars, 20μm. All results are representative of at least three independent
experiments.
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Figure 3.16 LGR5+ AM-EpiSCs resist to the BRAF inhibitor. A Immunohistochemistry
study showed BRAFV600E mutation in primary AM tissues. B 3D-organoids formed by AM
epithelial cells for 4 days were treated with PLX4032 (20μM) for 6 days. Upper: PLX4032
interfered with 3D-organoid formation as determined by H & E staining. Lower: the
residual PLX4032-resistant AM epithelial cells cells in 3D-organoids were positive for
LGR5 as determined by immunofluorescence study. N=3. Scale bars, 20μm.
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Figure 3.17 LGR5+ AM-EpiSCs resist BRAFV600E inhibitor and drug-resistant
LGR5+ AM-EpiSCs possess propagating ability to generate AM organoids. A
LGR5+ epithelial cells were enriched with a concomitant dose-dependent increase in the
expression of ALDH1, active β-catenin (ABC) and fibronectin but decreased E-cadherin
expression in either primary AM epithelial cells or AM-1 cells following treatment with
different concentrations of PLX4032 under 2D-monolayer culture condition for 48h. B
AM-1 cells were treated with PLX4032 (20μM) under 2D monolayer culture conditions for
48h and then LGR5- and LGR5+ AM epithelial cells were sorted by anti-LGR5
microbeads. The expression of stem cell- and EMT-related genes/markers was
significantly increased in LGR5+ AM epithelial cells in comparison to that in LGR5counterparts as determined by Western blot analysis. C and D AM-1 were treated with
PLX4032 (20μM) or vehicle under 2D-monolayer culture condition for 48h and LGR5and LGR5+ AM epithelial cells were sorted by anti-LGR5 microbeads. Unsorted
PLX4032-treated parental cells (PLX-parental) and sorted PLX4032-treated LGR5+
(PLX-LGR5+) cells generated significantly larger and more organoids than the PLXLGR5- counterparts and even the vehicle-treated parental group. Vehicle: Dimethyl
sulfoxide (DMSO). E Measurements of organoid number and size as shown in (D). Data
are Mean ± SD, n=3, one-way ANOVA and Dunnett’s post-test. ****p<0.0001. All results
are representative of at least two to three independent experiments.
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3.8 AM-MSC-derived secretomes promote the formation of
LGR5+ AM-EpiSC in vitro
Our recent studies have shown that AM-MSCs promoted EMT and
acquisition of stem cell properties in AM epithelial cells24. This study then aimed
to explore whether AM-MSCs can promote the formation of LGR5+ AM-EpiSCs.
To this purpose, AM-1 cells were co-cultured with AM-MSCs in a trans-well
system or with the AM-MSC derived conditioned medium (CM) for 3 days. The
results showed that co-culture with AM-MSCs or stimulation with AM-MSC
derived CM significantly changed the morphology of AM-1 from epithelial islands
to anastomosing strands (Figure 3.18 A). The Western blot study showed an
increase in the expression of LGR5, ALDH1, active β-catenin and fibronectin, but
decreased expression of E-cadherin in AM-1 cells following co-culture with AMMSCs or stimulation with AM-MSC derived CM (Figure 3.18 B), suggesting that
AM-MSC derived secretomes can promote EMT process and the formation of
LGR5+ AM-EpiSCs in AM epithelial cells. Then, AM-1 cells were further
stimulated with concentrated AM-MSC derived CM for 72h. The results showed
that stimulation with concentrated AM-MSC derived CM increased the expression
of LGR5, active β-catenin (ABC), and fibronectin in AM-1 cells as determined by
flow cytometry (Figure 3.18 C and D) and Western blot analysis (Figure 3.18 E),
respectively. To further define whether AM-MSC derived EVs play a role in this
process, AM-MSCs were pretreated with GW4869, a specific exosome secretory
blocker, for 24 or 72h, and then the conditioned medium was harvested for
functional studies. The results showed that pretreatment with GW4869 partially
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abrogated the upregulation of active β-catenin (ABC) and fibronectin expression
in AM-1 induced by AM-MSCs derived CM (Figure 3.18 F and G). These results
implicate that AM-MSC derived secretomes containing EVs contribute an
important role in promoting EMT process and formation of LGR5+ AM-EpiSCs in
AM epithelial cells.
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Figure 3.18 AM-MSC derived secretomes promote the subpopulation of LGR5+ AMEpiSC in vitro. A and B, AM-1 cells were seeded on a 6-well plate (3x105/well)
overnight and then co-cultured with AM-MSCs (2x105 cells) in serum free α-MEM or
treated with AM-MSC condition medium (CM) (collected from the AM-MSC cultured in
serum free α-MEM for 48h) for 3 days. Control: normal epithelial culture medium (KGM2)
and serum free α-MEM. A The morphology of AM-1 was changed by AM-MSC coculture or CM form multiple epithelial islands (KGM2 and α-MEM groups) to
anastomosing strands (MSC and MSC-CM groups). B Western blots study showed
increased expression of LGR5, stemness-related marker (ALDH1) and EMT- related
markers (ABC and fibronectin) and decreased expression E-cadherin. C AM-1 cells
treated with concentrated condition medium (C-CM) of AM-MSC for 3 days and the flow
cytometric results showed significantly increased expression of LGR5. Red: LGR5. Gray:
negative control. D The quantification of data shown in (C). Mean ± SD, two-tailed
unpaired Student’s t-tests. ***p<0.001. E Western blot study showed increased
expression of LGR5 and EMT-related makers (ABC and fibronectin) in AM-1 after
stimulated with concentrated condition medium (C-CM) of AM-MSC for 3 days. F The
diagram of AM-MSC treated with DMSO or GW4869 for 24h or 72h. The treated AMMSC CM were collected after 48h culturing. G AM-1 cells were stimulated with AM-MSC
CM (the AM-MSCs were treated with DMSO or GW4869 as the diagram shown in F)
showed either 24h or 72h treated AM-MSC derived CM reduced the expression of ABC
and fibronectin.
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3.9 Generation of 3D organoid model from AM epithelial cells
and AM-MSCs
To recapitulate the microenvironment of AM, AM epithelial cells and AMMSCs were combined to generate 3D organoid model. AM epithelial cells were
mixed with AM-MSCs in different cell ratios (1:1, 1:2, 1:4 and 2:1) and different
culture medium (data unshown), and defined an optimal cell ratio (2:1), cell
density (4x104 cells/μl Matrigel) and the culture condition that could facilitate AM
3D-organoid formation to recapitulate the histopathological properties and
maintained a similar expression of biomarkers in AM tissues. The AM epithelial
cells maintained the repropagating ability through several passages and
cryopreservation/thaw procedures (Figure 3.19). The cryopreserved organoids
were thawed into Matrigel to maintain in the organoid culture condition. The AM
organoids derived from AM epithelial cells and AM-MSCs self-organized to cystic
structures within 2 days under the microscopic examination (Figure 3.20 A). The
H & E study of the organoids derived from AM-1 mixed with AM-MSCs showed
plexiform-like anastomosing strands (Figure 3.20 B). To maintain a sufficient
nutrition supply in the central part of organoids, the AM organoids were
dissociated on day 4 and passaged to new Matrigel or cryopreserved. The
immunofluorescence study of day 2 organoids showed the expression of Ecadherin, CD90, vimentin and LGR5 in the AM organoids derived from AM-1 and
AM-MSCs (Figure 3.20 C and 3.21), and the day 4 organoids showed higher
expression of LGR5 than day 2 and day 8. Besides, the MSC marker (vimentin)
was losing in the Matrigel-culture condition (Figure 3.22). These present results
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have provided a short-term AM 3D-organoid platform to evaluate the potential
role of stromal cells in pathogenesis of AM.
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Figure 3.19 Long-term AM-organoid culture. A AM-organoids derived from AM-1
mixed with AM-MSCs (without GFP). The AM-organoids were passaged and
cryopreserved between P2 and P3. Each passage of AM-organoids maintained
propagating ability and continuingly generated new AM-organoids. Scale bars, 100μm. B
AM-organoids derived from AM-1 mixed with AM-MSCs-GFP were successfully
passaged and both AM-1 and AM-MSCs had cell viability and capacity to aggregate
together. Scale bars, 100μm.
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Figure 3.20 AM 3D-organoids derived from AM epithelial cells and AM-MSCs. A
Left: the diagram showing the generation of 3D-organoids by AM epithelial cells and AMMSCs. Ex vivo expanded primary AM epithelial cells/ AM-1 cells and primary AM-MSCs
(with GFP). Then primary AM epithelial cells or AM-1 were mixed with AM-MSCs (cell
ratio 2:1) and transferred to 3D Matrigel (4x104 cells/μl Matrigel). Right: Organoids
derived from AM-1 mixed with AM-MSCs (with GFP) under microscopic study. On day 0,
every single cell was suspended in Matrigel and then re-arranged into multicystic
structures within 2 days. Scale bars, 100μm. B 3D-organoid culture of plexiform AM-1
with AM-MSCs for 2 days. H&E staining showed generated organoids with irregular
epithelial islands connected as anastomosing strands that recapitulated the
histopathological features of plexiform AM. Scale bars, 20μm C 3D-organoid culture of
AM-1 (plexiform type) mixed with AM-MSCs (with GFP) for 2 days. Both epithelial (Ecadherin) and MSC (CD90 and vimentin) markers were showed in the organoids. Scale
bars, 20μm. All results are representative of three independent experiments.
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Figure 3.21 Expression of LGR5 in AM 3D-organoids derived from AM epithelial
cells and AM-MSCs. A AM-1 cells were mixed with AM-MSCs (with GFP) in cell ratio
2:1, and transferred to 3D Matrigel (4x104 cells/μl Matrigel) and the organoids were
harvested on day 2, 4 and 8. The expression of LGR5 was higher on day 4 while
compared with day 2 and day 8. Scale bars, 20μm. B Day 4 organoids derived from AM1 cells and AM-MSCs (without GFP). The immunofluorescence study showed the
majority of LGR5 signal was colocalized with E-cadherin (ECAD). Scale bars, 20μm. C
The quantification of the mean fluorescence intensity of the expression of LGR5 in the
AM organoids on day2, day4 and day8. Mean ± SD, one-way ANOVA. ****p<0.0001. D
The quantification of correlation coefficient of the expression of LGR5 and GFP; LGR5
and ECAD in the day 4 AM organoids. Mean ± SD, two-tailed unpaired Student’s t-tests.
****p<0.0001. All results are representative of two independent experiments.
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Figure 3.22 Loss of MSC-related gene (vimentin) expression in long-term AMorganoid culture. AM epithelial cells (follicular type) mixed with AM-MSCs in 3D
organoid culture for 3 months. During the 3D-organoid culturing, the epithelial marker (Ecadherin) was increased, but the EMT marker (vimentin) was decreased. Scale bars,
20μm. This long-term observation was performed once.
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3.10 AM-MSC derived secretomes promote the formation of
LGR5+ AM-EpiSC in vivo
To identify whether the AM-MSCs promote the generation of LGR5+ AMEpiSCs in vivo, AM epithelial cells (parental, sorted LGR5 - and sorted LGR5+)
were mixed with AM-MSCs in 1:1 ratio, respectively, and cultured in Matrigel for
three weeks. Then the organoids with Matrigel were implanted into the flank of
nude mice (n=3 for each group) (Figure 3.23 A). After two weeks, the xenografts
were harvested and embedded in OCT for frozen section. Interestingly, the
organoid xenografts with LGR5- AM epithelial cells alone could not survive in vivo
(Figure 3.12 B), but LGR5- AM epithelial cells mixed with AM-MSCs could form
tumor-like structures (Figure 3.23 B) similar to those formed by parental AM
epithelial cells or LGR5+ AM-EpiSCs mixed with AM-MSCs as shown by H & E
staining. In addition, dual-color immunofluorescence studies showed colocalized
expression of human LGR5 and proliferating cell nuclear antigen (PCNA) in
tumor-like structures formed by all groups of AM epithelial cells mixed with AMMSCs (Figure 3.23 C and D). Collectively, these findings suggest that AM-MSCs
can promote the formation of LGR5+ AM-EpiSCs both in vitro and in vivo through
their secretomes.
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Figure 3.23 AM-MSC promote the subpopulation of LGR5+ AM-EpiSC in vivo. A The
diagram showing the subcutaneous nude mice model using ex vivo organoids derived
from the mixture of AM epithelial cells and AM-MSCs. Following culturing in 3D Matrigel
for three weeks, the ex vivo organoids formed by AM epithelial cells (parental, sorted
LGR5+ or LGR5-) mixed with AM-MSCs were harvested and subcutaneously
transplanted into the flank of nude mice. B Two weeks post-transplantation, the tumorlike structures formed in nude mice were harvested for histological analysis by H & E
staining. The group of LGR5- AM epithelial cells with AM-MSCs could generate some
similar tumor-like structures as the groups of LGR5+/ parental with AM-MSCs. Scale
bars, 20μm. C Co-expression of LGR5 and proliferating cell nuclear antigen (PCNA) in
xenografted tumor-like structures formed by transplanted LGR5- AM epithelial cells with
AM-MSCs and parental epithelial cells/ LGR5+ AM-EpiSCs with MSCs as determined by
immunofluorescence studies. Scale bars, 100µm. D The quantification of relative
expression of PCNA, LGR5 and PCNA/LGR5 (P/L) from the results shown in (C). Mean
± SD (n=4 in each group, each group was measured 5 different random areas under the
microscope, two-tailed unpaired Student’s t-test. NS=not significant).
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CHAPTER 4: DISCUSSIONS AND CONCLUSIONS
4.1 The intermediate EMT stem-like LGR5+ epithelial cells in
ameloblastoma
Most solid tumors are composed of heterogeneous populations of tumor
cells with subpopulations endowed with increased self-renewal and tumor
repropagating capabilities termed cancer stem cells (CSCs) or tumor initiating
cells (TICs)19. To date, a panel of cell surface molecules such as CD133, CD44,
epithelial cell-adhesion molecule (EpCAM), CD166, CD151, etc., has been
utilized for identification of CSCs in distinct types of cancer19,72. LGR5, upon
binding with R-spondins, triggers the activation of downstream Wnt/β-catenin
signaling pathway25, and has also been used as a putative marker for CSCs in
several types of cancers29-34. However, like other adult stem cells, no single
molecule can serve as an exclusive marker for a specialized CSC compartment.
Multiple markers alone or in combination with ALDH enzyme activity and/or the
expression of stemness-regulatory genes, like OCT4, Nanog, and SOX2, have
been utilized to identify a special CSC subpopulation in different tumors72. In the
last decade, the critical role of CSCs or TICs in tumorigenesis, progression and
therapeutic relapse has been extensively explored and CSC-targeting therapies
are emerging as novel strategies in therapeutics of various cancers 19,20. However,
up to date, limited work has been done to explore the potential role of tumor stem
cells in the pathogenesis and therapy of various benign tumors of jaw bones,
including the most common type of odontogenic benign, yet most aggressive and
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devastating tumor, ameloblastoma. Developmentally, ameloblastoma may have
possibly derived from remnants of odontogenic epithelium, the migrating
epithelium at the cervical loop, and lining of odontogenic cyst 36,37, while LGR5
has been well recognized as putative marker for odontogenic epithelial stem
cells38-41. Herein, this study demonstrated that different subtypes of solid
ameloblastoma (AM) tissues harbored a subpopulation of LGR5 + epithelial cells
co-expressing stemness-related genes such as active β-catenin (ABC), OCT4
and ALDH1 as well as EMT-related genes such as ZEB1 and fibronectin, all of
which were significantly increased in isolated epithelial cells (AM-EpiSCs) when
cultured under 3D spheroid-forming conditions (Figure 3.1-3.8). Meanwhile,
purified LGR5+ AM epithelial cells displayed enhanced capacities to form 3Dspheroid in vitro and to generate tumor-like structures in vivo (Figure 3.6, 3.8 and
3.12-3-14). These findings support the hypothesis that LGR5 + epithelial cells in
ameloblastoma (AM) represent a subpopulation of epithelial tumor stem-like cells
(LGR5+ AM-EpiSCs) harboring an intermediate EMT phenotype, which may
contribute to the pathogenesis and recurrence of this benign/yet aggressive
odontogenic tumor.
BRAFV600E mutation has been implicated in the progression of several types
of carcinoma by RAS-independent activation of MEK/ERK signaling pathways 73.
This mutation has also been reported in about 46-82% of AM cases7-12, but it has
no relation to the high recurrence of AM. To date, several small molecular
inhibitors that specifically target BRAFV600E mutation have been developed as
therapeutic drugs for cancers with this mutant, but the development of intrinsic
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and acquired resistance to these drugs has become an ongoing challenge for the
treatment of these cancer patients73. Currently, an active clinical trial
(NCT02367859) is undergoing with the combinatory use of Dabrafenib and
Trametinib in the treatment of AM, but the clinical outcome is still unknown. In the
present study, the 3D-organoid platform generated by AM epithelial cells were
utilized to evaluate their response to treatment with Vemurafenib (PLX4032), a
selective inhibitor of BRAFV600E mutation. Even though PLX4032 interfered with
the cell viability and organoid formation by AM epithelial cells, it simultaneously
enriched the proportion of LGR5+ AM-EpiSCs with EMT phenotype and
enhanced capacity for organoid formation (Figure 3.15-3.17). Previous study also
showed increased LGR5 positive cells in colorectal xenograft after BRAF inhibitor
treatment74. These findings suggest that LGR5+ AM-EpiSCs are resistant to a
selective BRAFV600E inhibitor and the 3D-organoids derived from AM epithelial
cells could be a helpful platform to further screen small molecules that can
specifically target LGR5+ AM-EpiSCs and treat one of the most aggressive
benign tumors of the jaw bones.

4.2 Establishment of 3D-organoid culture for tumor study
Traditional two-dimensional (2D) monolayer cell culture has long been a
mainstay in the field of biomedical research. However, it is a great challenge to
maintain the intrinsic cell properties and retain the molecular and epigenetic
repertoire due to the lack of supporting niche factors. In recent years, 3Dorganoid culture is emerging as a novel approach in cell biology, particularly in
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stem cell research and cancer cell biology, which enables modeling the tumor
microenvironment and maintaining the major genetic and phenotypic features of
individual tumors in an efficient and cost-effective manner49,69,71. Organoid and
spheroid cultures allow for better modeling cell behaviors in a recapitulating in
vivo-like natural tumor microenvironment such as cell-cell interactions, hypoxia,
pH gradients, extracellular matrix, and different profile of bioactive molecules 50.
For instance, the cell-cell and cell-ECM interactions and cell geometry in 3D
culture can increase self-renewal ability and the expression of stem cell-related
genes, such as OCT4 and Nanog75-77, thus allowing for maintenance and
expansion of normal and cancer stem cells50. Under most conditions, 3D
organoid cultures require mouse-derived extracellular matrix (ECM) substitutes
with variant stiffness or rigidity e.g. Matrigel or basement membrane extract,
which may affect the outcome of experiments49. Most recently, mechanically and
chemically defined hydrogel matrices with controllable substrate stiffness and
rigidity have been developed for organoid culture of patient-derived colorectal
tumors78. In the present study, mouse-derived ECM were utilized for AM
organoid culture, which led to maintenance and expansion of LGR5 + AM-EpiSCs
(Fig. 3.11). However, further studies are warranted to explore the mechanisms
whereby mechanical properties of ECM and other factors enhance the selfrenewal and expansion of this subpopulation of AM-EpiSCs.
In addition, organoids can be used, to certain degrees, as preclinical
alternative models to animal models because they can reduce experimental
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complexity, allow real-time imaging and high-throughput screening, and enable
the study of diseases that are not easily and accurately modelled in animals 48. To
date, numerous organoids have been reported for various types of cancers for
multiple purposes, e.g. disease modeling, mechanistic study, biobanking, drug
screening, prediction of treatment response, and so on 49,69,71. However, much
less work has been done to develop an organoid platform to model a benign
tumor even though it is usually challengeable to establish an appropriate animal
model for most types of benign tumors. This study demonstrated for the first time
the feasibility to generate 3D organoid structures of human ameloblastoma by
using AM epithelial cells with or without AM-MSCs, which recapitulated the
histopathological features and LGR5 expression profile of distinct subtypes of
solid ameloblastoma and could be passaged and cryopreserved (Figure 3.11 and
3.19-3.21). Interestingly, in the 3D-orgnoid model derived from both AM epithelial
cell and AM-MSCs, the MSC markers were losing during long-term culture
(Figure 3.22), and the similar finding was reported that only epithelial markers
were detected in patient derived organoids from other tissues including head and
neck cancers79. In the transplanted organoid xenograft model, the LGR5 + AMEpiSCs had propagating ability and could generated some tumor-like structures.
However, it is noteworthy that, even though a short-term subcutaneous
transplantation of AM 3D-organoids into nude mice led to xenograft formation
(Fig. 3.12-3.14), demonstrating the self-renewal and propagating capabilities of
LGR5+ EpiSCs in vivo, this study still cannot establish an appropriate animal
model for long-term observation of the role of this unique subpopulation of
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epithelial stem-like cells in the initiation and progression of AM, a common
challenge for most types of benign tumors due to their intrinsically benign and
slow progression properties.

4.3 The reciprocal crosstalk of tumor microenvironment and
tumor stem cells
To date, several hypotheses have been proposed on different origins of
CSCs in individual tumors, such as normal tissue stem and progenitor cells, the
more differentiated somatic cells, and lineage infidelity switching triggered by
microenvironmental stress signals19,80. Accumulating evidence support the notion
that CSCs represent a dynamic or plastic status, whereby tumor cells can
convert or reprogram between stem and non-stem cell state or phenotype due to
the signals they encounter within the tumor microenvironment (TME), e.g.
chronic inflammation and therapeutic insults19,22. The dynamic bidirectional
phenotypic conversion between non-CSCs and CSCs may contribute to the
development of heterogeneity of CSCs, e.g. distinct quiescence, therapeutic
sensitivity, and capabilities for EMT, invasion, and metastasis19,22. EMT is a
complex reprogramming process through which epithelial cells acquire a
mesenchymal or epithelial/mesenchymal hybrid cell phenotype, which plays an
important role in regulating plasticity of CSCs21-23. A large panel of growth factors,
cytokines, chemokines and other stimuli within the tumor microenvironment can
trigger epithelial tumor cells to undergo EMT and acquire stem cell properties72.
In the present study, R-spondin 2 could stimulate the proliferation and induce
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EMT in ameloblastoma epithelial cells (AM epithelial cells) was showed,
suggesting that

LGR5/R-spondin

2 may functionally contribute to the

development and maintenance of the hybrid EMT phenotype of ameloblastoma
epithelial stem-like cells (AM-EpiSCs). Most recently, this study have shown that
ameloblastoma mesenchymal stromal cells (AM-MSCs) promote EMT and
increase the expression of certain stemness-regulatory genes in AM epithelial
cells through their secretion of interleukin (IL)-624. In this study, to elucidate the
role of AM-MSCs in regulating the plasticity and homeostasis of LGR5+ AMEpiSCs, the AM-MSC derived conditioned medium was utilized to stimulate the
AM epithelial cells. The results showed the AM-MSC derived secretomes/EVs
enhanced the expression of EMT markers (active β-catenin and fibronectin) and
contributed to the subpopulation of LGR5+ AM-EpiSCs (Figure 3.18). Of note, the
AM-MSC derived EVs may play partial role to promote the EMT process of AM
epithelial cells, and the EV dependent and independent effects on AM epithelial
cells are warranted to define in future studies. Besides, the AM-MSCs promoted
the LGR5- AM epithelial cells to form some tumor-like structures and increased
the subpopulation of LGR5+ cells in nude mice as the parental and LGR5+ groups
that implicated AM-MSCs could maintain the homeostasis of LGR5+ AM-EpiSCs
in vivo (Figure 3.23). These results support the hypothesis that AM-MSCs
contribute to the homeostasis of LGR5+ AM-EpiSCs, however, further studies are
needed in an appropriate animal model for long-term observation to demonstrate
the roles of stromal cells in the homeostasis of LGR5+ stem-like cells in AM.
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4.4 Limitations and future directions
The major limitation of this study is limited resource of fresh samples.
Therefore, AM cell lines were utilized to validate the results of the primary cells
and for mechanism studies. However, cell lines may undergo chromosomal
rearrangements/duplications or mutations, and epigenetic changes that make cell
lines could not recapitulate the primary tumor behaviors51,52. In the future, we
would like to collaborate with multicenter in the USA and worldwide, such as
China and Taiwan, to establish a cell/tissue bank of ameloblastoma. After
establishing the AM cell/tissue bank, we want to create a patient derived
organoid platform and animal models for small molecular screenings and further
mechanistic studies.
This study demonstrated that AM-MSC derived secretomes maintain the
homeostasis of LGR5+ AM-EpiSCs. In future non-surgical adjuvant therapeutic
studies,

directly

targeted

inhibition

of

LGR5

and

blockage

of

the

microenvironment factors that promote the homeostasis of LGR5+ AM-EpiSCs
serve novel approaches for this aggressively benign jaw tumor. Hence, it is vital
to dissect major factors of AM-MSC derived secretomes or EVs that govern the
EMT process and stem cell properties in LGR5+ AM epithelial cells, and we will
define stroma derived EV dependent and independent effects on AM epithelial
cells. First, AM-MSC derived EVs and characterize its size, markers and
interactions with AM epithelial cells will be isolated. Secondly, we will determine
and compare the major components, such as R-spondin, IL-6 and PGE2, of AMMSC derived EVs and non-EVs by microarray analysis. We will identify whether
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these defined major factors can promote the EMT process and stem cell
properties in LGR5+ AM-EpiSCs and promote the formation of LGR5+ AMEpiSCs. Finally, elusive molecular mechanisms of these defined major factors
from stroma derived EVs and non-EVs that govern the EMT process and stem
cell properties in LGR5+ AM-EpiSCs will be determined.
In addition, the ex vivo 3D organoid models are possible for quick drug
screening, but limited in a short-term culturing, that obstructs further mechanistic
studies.

To

supply

consistent

nutrition

and

mimic

the

physiological

microenvironment, we will optimize the ex vivo culture condition and the in vivo
subcutaneous organoid model and hope to develop an intraosseous organoid
model in the jaw of nude mice for mechanistic and therapeutic intervention
studies.

4.5 Clinically relevant and conclusion
In conclusion, this is the first study to identify a subpopulation of LGR5 +
epithelial cells endowed with tumor stem-like cell properties and intermediate
EMT phenotype in solid AM (LGR5+ AM-EpiSCs), which may play an important
role in its pathogenesis and recurrence. In addition, this study established
conditions for generation of 3D AM-organoids which recapitulate certain degree
of different histological subtypes of AM, thus allowing us to generate 3D AM
organoids by directly using both biopsy and final excisional tissues from AM in
the future. In the short term, the human AM 3D-organoids may be utilized as a
platform for further mechanistic studies and screening small molecules that can
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specifically target LGR5+ AM-EpiSCs due to the lack of an animal model for AM.
In the long run, further studies are warranted to optimize the conditions for
generation and transplantation of 3D AM-organoids in order to generate a
consistent animal model of AM for deep mechanistic and interventional studies in
vivo.
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APPENDIX I: Supplemental data of Western blots
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APPENDIX II: Negative controls of
Immunohistochemical and immunofluorescence studies

*The negative control was representative of images whereby sections or cells were incubated at 4 degree overnight with
the appropriate isotype-matched negative control IgG with an equal concentration of the match primary antibody, followed
by incubation with the corresponding secondary antibody as described in Materials & Methods.
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*The negative control was representative of images whereby sections or cells were incubated at 4 degree overnight with
the appropriate isotype-matched negative control IgG with an equal concentration of the match primary antibody, followed
by incubation with the corresponding secondary antibody as described in Materials & Methods.
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*The negative control was representative of images whereby sections or cells were incubated at 4 degree overnight with
the appropriate isotype-matched negative control IgG with an equal concentration of the match primary antibody, followed
by incubation with the corresponding secondary antibody as described in Materials & Methods.
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APPENDIX III: Measurement of coefficient
In this study, the coefficient of two channels in the immunofluorescence
study was processed by the CellProfiler software, and one demo is presented
below.
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